Embodiments described herein relate generally to delivering a fluid to a patient, and more particularly to devices and methods for delivering a parenteral fluid to a patient with reduced contamination from microbes or other contaminants exterior to the body and/or the fluid source, such as dermally residing microbes.
Human skin is normally habituated in variable small amounts by certain bacteria such as coagulase-negative Staphylococcus species, Proprionobacterium acnes, Micrococcus species, Streptococci Viridans group, Corynebacterium species, and Bacillus species. These bacteria for the most part live in a symbiotic relationship with human skin but in some circumstances can give rise to serious infections in the blood stream known as septicemia. Septicemia due to these skin residing organisms is most often associated with an internal nidus of bacterial growth at the site of injured tissue, for example a damaged, scarred heart valve, or a foreign body (often an artificial joint, vessel, or valve). Furthermore, there are predisposing factors to these infections such as malignancy, immunosuppression, diabetes mellitus, obesity, rheumatoid arthritis, psoriasis, and advanced age. In some instances, these infections can cause serious illness and/or death. Moreover, these infections can be very expensive and difficult to treat and often can be associated with medical related legal issues.
In general medical practice, blood is drawn from veins (phlebotomy) for two main purposes; (1) donor blood in volumes of approximately 500 mL is obtained for the treatment of anemia, deficient blood clotting factors including platelets and other medical conditions; and (2) smaller volumes (e.g., from a few drops to 10 mL or more) of blood are obtained for testing purposes. In each case, whether for donor or testing specimens, a fluid communicator (e.g., catheter, cannula, needle, etc.) is used to penetrate and enter a vein (known as venipuncture) enabling withdrawing of blood into a tube or vessel apparatus in the desired amounts for handling, transport, storage and/or other purposes. The site of venipuncture, most commonly the antecubital fossa, is prepared by cleansing with antiseptics to prevent the growth of skin residing bacteria in blood withdrawn from the vein. It has been shown venipuncture needles dislodge fragments of skin including hair and sweat gland structures as well as subcutaneous fat and other adnexal structures not completely sterilized by skin surface antisepsis. These skin fragments can cause septicemia in recipients of donor blood products, false positive blood culture tests and other undesirable outcomes. Furthermore, methods, procedures and devices are in use, which divert the initial portion of venipuncture blood enabling exclusion of these skin fragments from the venipuncture specimen in order to prevent septicemia in recipients of donor blood products, false positive blood culture tests and other undesirable outcomes.
Venipuncture is also the most common method of accessing the blood stream of a patient to deliver parenteral fluids into the blood stream of patients needing this type of medical treatment. Fluids in containers are allowed to flow into the patient's blood stream through tubing connected to the venipuncture needle or through a catheter that is placed into a patient's vasculature (e.g. peripheral IV, central line, etc.). During this process, fragments of incompletely sterilized skin can be delivered into the blood stream with the flow of parenteral fluids and/or at the time of venipuncture for introduction and insertion of a peripheral catheter. These fragments are undesirable in the blood stream and their introduction into the blood stream of patients (whether due to dislodging of fragments by venipuncture needle when inserting a catheter or delivered through tubing attached to needle or catheter) is contrary to common practices of antisepsis. Further, these microbes can be associated with a well-known phenomenon of colonization by skin residing organisms of the tubing and tubing connectors utilized to deliver parenteral fluids. The colonization is not typically indicative of a true infection but can give rise to false positive blood culture tests, which may result in unnecessary antibiotic treatment, laboratory tests, and replacement of the tubing apparatus with attendant patient risks and expenses. Furthermore, the risk of clinically significant serious infection due to skin residing organisms is increased.
As such, a need exists for improved fluid transfer devices, catheter introduction techniques and devices, as well as methods for delivering a parenteral fluid to a patient that reduce microbial contamination and inadvertent injection of undesirable external microbes into a patient's blood stream.
Devices and methods for delivering a fluid to a patient and/or introducing a peripheral catheter with reduced contamination from dermally residing microbes or other contaminants exterior to the body and/or an external fluid source are described herein. In some embodiments, an apparatus includes a cannula assembly, a housing, a fluid reservoir, a flow control mechanism, and an actuator. The housing has a proximal end portion and a distal end portion and defines an inner volume therebetween. The housing includes an inlet port removably coupled to the cannula assembly. The fluid reservoir is fluidically coupled to the housing and configured to receive and isolate a first volume of bodily fluid withdrawn from a patient. The flow control mechanism is at least partially disposed in the inner volume and is configured to move relative to the housing between a first configuration and a second configuration. The flow control mechanism defines a fluid flow path between the cannula assembly and the fluid reservoir in the first configuration. The actuator is operably coupled to the flow control mechanism to move the flow control mechanism from the first configuration, in which the inlet port is placed in fluid communication the fluid reservoir such that bodily fluid can flow from the cannula assembly, through the inlet port via the fluid flow path and to the fluid reservoir, to the second configuration, in which the fluid reservoir is fluidically isolated from the cannula assembly.
Devices and methods for delivering a fluid to a patient with reduced contamination from dermally residing microbes or other contaminants exterior to the body are described herein. In some embodiments, an apparatus includes a cannula assembly, a housing, a fluid reservoir, a flow control mechanism, and an actuator. The housing has a proximal end portion and a distal end portion and defines an inner volume therebetween. The housing includes an inlet port configured to be removably coupled to the cannula assembly. The fluid reservoir is fluidically coupled to the housing and configured to receive and isolate a first volume of bodily fluid withdrawn from a patient. The flow control mechanism is at least partially disposed in the inner volume and is configured to move relative to the housing between a first configuration and a second configuration. The flow control mechanism defines a fluid flow path between the cannula assembly and the fluid reservoir in the first configuration. The actuator is operably coupled to the flow control mechanism to move the flow control mechanism from the first configuration, in which the inlet port is placed in fluid communication the fluid reservoir such that bodily fluid can flow from the cannula assembly, through the inlet port via the fluid flow path and to the fluid reservoir, to the second configuration, in which the fluid reservoir is fluidically isolated from the cannula assembly.
In some embodiments, a device for delivering a fluid to a patient with reduced contamination includes a housing, a fluid reservoir, and a flow control mechanism. The housing has a proximal end portion and a distal end portion and defines an inner volume therebetween. The housing includes a first port configured to be removably coupled to a cannula assembly, and a second port configured to be fluidically coupled to a fluid source. The fluid reservoir is fluidically coupleable to the cannula assembly and configured to receive and isolate a predetermined volume of bodily fluid withdrawn from the patient. The flow control mechanism is at least partially disposed in the inner volume of the housing and is configured to move between a first configuration and a second configuration. When in the first configuration, the first port is placed in fluid communication with the fluid reservoir such that bodily fluid can flow from the cannula assembly, through the first port and to the fluid reservoir. When in the second configuration, the fluid reservoir is fluidically isolated from the cannula assembly and fluid can flow from the fluid source, in the second port, through the flow control mechanism, out the first port and to the cannula assembly.
In some embodiments, a method of delivering a fluid to a patient using a fluid transfer device includes establishing fluid communication between the patient and the fluid transfer device. Once in fluid communication, a predetermined volume of a bodily fluid is withdrawn from the patient. The predetermined volume of bodily fluid is transferred to a fluid reservoir. The fluid transfer device is fluidically isolated from the fluid reservoir to sequester the predetermined volume of bodily fluid in the fluid reservoir. The method further includes establishing fluid communication between the patient and a fluid source with the fluid transfer device.
In some embodiments, an apparatus includes a housing, a cannula assembly, a flow control mechanism, and a fluid reservoir. The flow control mechanism is configured to move relative to the housing between a first configuration and a second configuration. The cannula assembly is coupled to the housing and fluidically coupled to the fluid reservoir when the flow control mechanism is in the first configuration. The fluid reservoir is fluidically isolated from the cannula assembly when the flow control mechanism is in a second configuration such that the cannula assembly can be fluidically coupled to an external fluid reservoir and/or an external fluid source.
As referred to herein, “bodily fluid” can include any fluid obtained from a body of a patient, including, but not limited to, blood, cerebrospinal fluid, urine, bile, lymph, saliva, synovial fluid, serous fluid, pleural fluid, amniotic fluid, and the like, or any combination thereof.
As used herein, the term “set” can refer to multiple features or a singular feature with multiple parts. For example, when referring to set of walls, the set of walls can be considered as one wall with distinct portions, or the set of walls can be considered as multiple walls. Similarly stated, a monolithically constructed item can include a set of walls. Such a set of walls can include, for example, multiple portions that are in discontinuous from each other. A set of walls can also be fabricated from multiple items that are produced separately and are later joined together (e.g., via a weld, an adhesive or any suitable method).
As used in this specification, the words “proximal” and “distal” refer to the direction closer to and away from, respectively, a user who would place the device into contact with a patient. Thus, for example, the end of a device first touching the body of the patient would be the distal end, while the opposite end of the device (e.g., the end of the device being manipulated by the user) would be the proximal end of the device.
The transfer device 100 includes a housing 101, a cannula assembly 120, a fluid reservoir 130, a flow control mechanism 140, and an actuator 180. The housing 101 can be any suitable shape, size, or configuration and is described in further detail herein with respect to specific embodiments. As shown in
The cannula assembly 120 can be any suitable configuration. For example, in some embodiments, the cannula assembly 120 includes an engagement portion and a cannula portion (not shown in
As shown in
The flow control mechanism 140 included in the transfer device 100 is disposed, at least partially, within the inner volume 111 of the housing 101 and can be moved between a first configuration (
In some embodiments, the transfer device 100 can include an actuator 180 operably coupled to the flow control mechanism 140 and configured to move the flow control mechanism 140 between the first and the second configuration. For example, in some embodiments, the actuator 180 can be a push button, a slider, a toggle, a pull-tab, a handle, a dial, a lever, an electronic switch, or any other suitable actuator. In this manner, the actuator 180 can be movable between a first position corresponding to the first configuration of the flow control mechanism 140, and a second position, different from the first position, corresponding to the second configuration of the flow control mechanism 140. In some embodiments, the actuator 180 can be configured for uni-directional movement. For example, the actuator 180 can be moved from its first position to its second position, but cannot be moved from its second position back to its first position. In this manner, the flow control mechanism 140 is prevented from being moved to its second configuration before its first configuration, as described in further detail herein.
In use, the flow control mechanism 140 can be in the first configuration to place the fluid reservoir 130 in fluid communication with the cannula assembly 120, as indicated by the arrow AA in
While shown in
In some embodiments, the movement of the flow control mechanism 140 to the second configuration can substantially correspond to a physical and fluidic decoupling of at least a portion of the housing 101 from the cannula assembly 120 such that an external fluid reservoir 199 (e.g., also referred to herein as “fluid source”) can be physically and fluidically coupled to the cannula assembly 120. For example, as shown in
While the housing 101 is shown in
As shown in
The housing 201 can house or define at least a portion of the fluid reservoir 230. Similarly stated, the fluid reservoir 230 can be at least partially disposed within the inner volume 211 of the housing 201. The fluid reservoir 230 can receive and fluidically isolate a predetermined amount of the bodily fluid, as described above in reference to
In use, the flow control mechanism 240 can be placed in the first configuration to fluidically couple the cannula assembly 220 to the fluid reservoir 230 via the first lumen 246. In this manner, a flow of a bodily fluid can be delivered to the fluid reservoir 230, as indicated by the arrow DD in
With a predetermined amount of bodily fluid disposed within the fluid reservoir 230, the flow control mechanism 240 can be moved (e.g., by an actuator and/or manual intervention from the user) to the second configuration to fluidically isolate the fluid reservoir 230 from the cannula assembly 220. More specifically, the flow control mechanism 240 can be moved from the first configuration to fluidically isolate the first lumen 246 from the cannula assembly 220 and/or the fluid reservoir 230, thereby fluidically isolating the fluid reservoir 230 from the cannula assembly 220. In addition, the movement of the flow control mechanism 240 to the second configuration can place the second lumen 247 in fluid communication with the cannula assembly 220 and the outlet port 206 (e.g., the second port) disposed at the proximal end portion 202 of the housing 201. Thus, the external fluid reservoir 299 can be fluidically coupled (as described above) to the second port 206 to deliver a flow of parenteral fluid to the patient via the second lumen 247 and the cannula assembly 220, as indicated by the arrow EE. For example, the flow of parenteral fluid can flow from the external fluid reservoir 299 (e.g., a fluid source), in the second port 206, through the second lumen 247 defined by the flow control mechanism 240, out the first port 205 and to the cannula assembly 220 to be delivered to the patient. Moreover, the flow of the parenteral fluid is substantially free from dermally residing microbes and/or other undesirable external contaminants.
In some embodiments, the transfer device 200 can be configured such that the first amount of bodily fluid needs to be conveyed to the fluid reservoir 230 before the transfer device 200 will permit the flow of the parenteral fluid to be conveyed through the transfer device 200 to the patient. In this manner, the transfer device 200 can be characterized as requiring compliance by a health care practitioner regarding the collection of the predetermined amount of bodily fluid prior to the delivery of the parenteral fluid. Similarly stated, the transfer device 200 can be configured to prevent a health care practitioner from delivering the parenteral fluid to the patient without first diverting or transferring the predetermined amount of bodily fluid to the fluid reservoir 230. In this manner, the health care practitioner is substantially prevented from introducing (whether intentionally or unintentionally) bodily surface microbes and/or other undesirable external contaminants into, for example, the flow of the parenteral fluid and/or the blood stream of the patient. In other embodiments, the fluid transfer device 200 need not include a forced-compliance feature or component.
The housing 301 includes a proximal end portion 302 and a distal end portion 303 and defines an inner volume 311 therebetween (see e.g.,
As shown in
As shown in
The flow control mechanism 340 included in the transfer device 300 is at least partially disposed within the inner volume 311 of the housing 301 and is configured to be moved between a first configuration and a second configuration. Expanding further, the flow control mechanism 340 is in the first configuration when disposed in a distal position relative to the housing 301 (see e.g.,
The second member 360 of the flow control mechanism 340 includes a proximal end portion 361 and a distal end portion 362 and defines a lumen 363 therethrough. As shown in
The distal end portion 362 of the second member 360 is configured to extend beyond a distal end of the cannula 324 included in the cannula assembly 320, when the flow control mechanism 340 is in the first configuration. Furthermore, the distal end portion 362 of the second member 360 can include a sharp point that can facilitate the insertion of the transfer device 300 (e.g., the flow control mechanism 340 and the cannula assembly 320) into a portion of a patient. For example, the distal end portion 362 of the second member 360 can be used to access a vein of the patient and facilitate the introduction of the cannula 324 into the vein. Moreover, with the cannula 324 and the distal end portion 362 of the second member 360 disposed within the vein of the patient the transfer device 300 can be configured to transfer a portion of a bodily fluid from the patient to the fluid reservoir 330 to prevent injection of dislodged dermally residing microbes that have been incompletely sterilized by surface antisepsis and/or other undesirable external contaminants.
As shown in
The increase of volume introduces a negative pressure within the inner volume 333 of the fluid reservoir 330 and within the inner volume 311 of the housing 301. Therefore, with the cannula 324 and the second member 360 of the flow control mechanism 340 disposed within the vein of the patient, the negative pressure urges a flow of bodily fluid (e.g., blood) through the lumen 363 and 346 defined by the second member 360 and first member 341 of the flow control mechanism 340, respectively. As indicated by the arrow GG in
As shown in
The proximal motion of the flow control mechanism 340 can be such that both the first member 341 and the second member 360 of the flow control mechanism 340 are disposed within the collective volume defined by the fluid reservoir 330 and the housing 301. Similarly stated, the spring 349 moves the flow control mechanism 340 in the proximal direction a sufficient distance to move the distal end portion 362 of the second member 360 through the port 305, the seal member 316, and the distal wall 308 to be disposed within the housing 301. Furthermore, the seal member 316 can be configured such that as the distal end portion 362 passes beyond the distal wall 308 of the housing 301, the seal member 316 acts to seal the opening 309 through which the second member 360 was disposed. Thus, when the flow control mechanism 340 is completely disposed within the collective volume defined by the housing 301 and the fluid reservoir 330 (e.g., the combination of the inner volume 311 and the inner volume 333, respectively), the seal member 316 seals the distal end portion 303 of the housing 301 and the fluid reservoir 330 is substantially fluidically isolated from the cannula assembly 320.
With the fluid reservoir 330 fluidically isolated from the cannula assembly 320, the transfer device 300 can be placed in a fourth configuration, as shown in
While the fluid reservoir 330 is shown in
The housing 401 of the transfer device 400 includes a proximal end portion 402 and a distal end portion 403 and defines an inner volume 411 therebetween. More specifically, the housing 401 is substantially closed at the proximal end portion 402 such that at the proximal end, the inner volume 411 is fluidically isolated from a volume outside the housing 401. The distal end portion 403 of the housing 401 is coupled to a port 405. The port 405 is substantially similar to the port 305 described above, and can be coupled to the distal end portion 403 of the housing 401 such that a seal member 416 is disposed between the port 405 and a distal wall 408 of the housing 401. In this manner, the seal member 416 can form a substantially fluid tight seal between the distal wall 408 and the port 405 (described in detail with reference the port 305 shown in
The fluid reservoir 430 included in the transfer device 400 is movably disposed within the inner volume 411 defined housing 401. More specifically, the fluid reservoir 430 is configured to move within the housing 401 between a first configuration (
As shown in
In use, the transfer device 400 can be moved from the first configuration (
The proximal motion of the flow control mechanism 440 moves within the inner volume 433 to place the first member 441 in contact with the proximal end portion 441 of the fluid reservoir 430. In this manner, the flow control mechanism 440 urges the proximal end portion 431 of the fluid reservoir 430 to move in the direction of the arrow JJ (e.g., the proximal direction). Moreover, the distal end portion 432 of the fluid reservoir 430 can be coupled to the distal wall 408 of the housing 401 such that as the proximal end portion 431 moves in the proximal direction, the fluid reservoir 430 expands. Similarly stated, the fluid reservoir 430 can form a bellows in which the proximal motion of the flow control mechanism 440 moves the fluid reservoir 430 from a compressed configuration (e.g., the first configuration) to an expanded configuration (e.g., the second configuration).
The movement of the proximal end portion 431 relative to the distal end portion 432 increases the inner volume 433 defined by the fluid reservoir 430 and introduces a negative pressure within the inner volume 433. Moreover, with the lumen 446 of the first member 441 and the lumen 463 of the second member 460 in fluid communication with the fluid reservoir 430, at least a portion of the negative pressure is transferred through the flow control mechanism 440. Therefore, while the flow control mechanism 440 is being moved to the second position (
With the fluid reservoir 430 fluidically isolated from the cannula assembly 420, the transfer device 400 can be placed in a third configuration, as shown in
With the port 405 decoupled from the lock mechanism 421, the fluid reservoir 430 can contain and fluidically isolate a portion of the bodily fluid (e.g., blood) that includes, for example, dermally residing microbes dislodged during the venipuncture event (e.g., the insertion of the distal end portion 462 of the second member 460 of the flow control mechanism 440). Furthermore, with the port 405 decoupled from the lock mechanism 421, the cannula assembly 420 can be physically and fluidically coupled to an external fluid reservoir (not shown in
While the fluid reservoir 430 is shown in
As shown in
Referring back to
As shown in
The flow control mechanism 540 included in the transfer device 500 is at least partially disposed within the inner volume 511 of the housing 501 and is configured to be moved between a first position and a second position. Expanding further, the flow control mechanism 540 is in the first position when disposed in a distal position relative to the housing 501 (see e.g.,
The distal end portion 543 of the first member 541 can have a second diameter, smaller than the first diameter, substantially corresponding to an inner diameter of a lock mechanism 521 included in the cannula assembly 520. For example, in some embodiments, the distal end portion 543 can extend through the opening 509 defined by the distal wall 508 of the housing 501 to be disposed within the lock mechanism 521. In some embodiments, the distal end portion 543 can form a friction fit with an inner surface of the lock mechanism 521 to removably couple the flow control mechanism 540 to the cannula assembly 520. Furthermore, with the proximal end portion 542 of the first member 541 disposed in a proximal position relative to the distal wall 508 and with the diameter of the proximal end portion 542 substantially larger than the diameter of the opening 509, the flow control mechanism 540 operatively couples the housing 501 to the cannula assembly 520.
The second member 560 of the flow control mechanism 540 includes a proximal end portion 561 and a distal end portion 562 and defines a lumen 563 therethrough. As shown in
For example, as shown in
With a predetermined amount of bodily fluid transferred to the fluid reservoir, the fluid reservoir can be decoupled from the port 583 (e.g., physically and fluidically or only fluidically). In this manner, a user can engage the first actuator member 581 to move the actuator mechanism 580 to its second configuration and thereby place the transfer device in a second configuration. For example, as indicated by the arrow MM in
The actuator mechanism 580 is such that the rotation of the first actuator member 581 urges the second actuator member 585 to also rotate relative to the housing 501. In this manner, a centerline defined by the flow control channel 587 is rotated from a first configuration in which the centerline is substantially perpendicular to the centerline defined by the inner volume 511 to a second configuration in which the centerline is substantially parallel to the centerline of the inner volume 511. Similarly stated, the second actuator member 585 is rotated such that the centerline defined by the flow control channel 587 is aligned with the centerline defined by the inner volume 511.
As shown in
The expansion of the spring 549 exerts a force on the first member 541 of the flow control mechanism 540 to move the flow control mechanism 540 in the proximal direction, as indicated by the arrow NN in
As shown in
While the transfer devices described above are configured to include a cannula assembly that is physically and fluidically decoupled from a portion of the transfer device to receive a parenteral fluid, in some embodiments, a transfer device can include a cannula assembly configured to remain physically coupled to a portion of the transfer device. For example,
As shown in
The distal end portion 603 of the housing 601 includes a distal port 605 and a reservoir seat 618. The reservoir seat 618 is configured to engage, at least temporarily, a portion of the fluid reservoir 630, as described in further detail herein. The distal port 605 is configured to be physically and fluidically coupled to a lock mechanism 621 included in the cannula assembly 620. For example, in some embodiments, the lock mechanism 621 can be a Luer-Lok® configured to receive the port 605. In other embodiments, the port 605 and the lock mechanism 621 can be coupled in any suitable manner such as, for example, a threaded coupling, a friction fit, or the like. In still other embodiments, the port 605 and the lock mechanism 621 can be coupled via an adhesive or the like to fixedly couple the cannula assembly 620 to the housing 601. With the lock mechanism 621 coupled to the port 605, the inner volume 611 of the housing 601 is in fluid communication with a cannula 624 included in the cannula assembly 620, as further described herein.
As described above, the fluid reservoir 630 is disposed within the inner volume 611 of the housing 601. More particularly, the fluid reservoir 630 is movably disposed within the inner volume 611 between a first position in which the fluid reservoir 630 is in a distal position relative to the housing 601 (see e.g.,
The distal end portion 632 of the fluid reservoir 630 includes a valve seat 637. The valve seat 637 includes a port 638 and receives a valve 639 (see e.g.,
As described above, the flow control mechanism 640 can be at least partially disposed within the housing 601. More particularly and as shown in
The plunger portion 650 of the flow control mechanism 640 is configured to extend in a distal direction from a surface of the engagement portion 645. The plunger 650 includes a first surface 652, a second surface 655, a protrusion 653, a first seal member 658, and a second seal member 659. As shown in
In use, the transfer device 600 can be moved between a first configuration (
As shown in
In addition, the first seal member 658 can engage an inner surface of the fluid reservoir 630 such that the proximal movement of the flow control mechanism 640 produces a negative pressure within a portion of the inner volume 633 of the fluid reservoir 630 (e.g., the portion of the inner volume 633 that is disposed distally relative to the first seal member 658). In this manner, the negative pressure introduces a suction force that can be operable placing the valve 639 in an open configuration. Thus, with the cannula 624 and the port 605 in fluid communication with the portion of the patient (e.g., the vein), a flow of bodily fluid (e.g., blood) can pass through the valve 639 and enter the inner volume 633 of the fluid reservoir 630, as indicated by the arrow QQ.
As shown in
With the transfer device 600 in the second configuration, a flow of a predetermined amount of bodily fluid can be transferred to the inner volume 633 of the fluid reservoir 630 that can include, for example, dermally residing microbes dislodged during a venipuncture event (e.g., the insertion of the cannula 624 into the vein and/or otherwise accessing the vasculature of the patient). In addition, when the predetermined amount of bodily fluid is transferred to the inner volume 633 of the fluid reservoir 630, the valve 639 can be placed in a closed configuration. For example, in some embodiments, the transfer of the predetermined amount of bodily fluid can be such that the negative pressure within the inner volume 633 is brought into equilibrium with the pressure of the vein, thus allowing the valve 639 to move to the closed configuration. In other embodiments, the valve 639 can be manually actuated by user interference (e.g., engagement of an actuator, a switch, a button, a toggle, or the like). In this manner, the bodily fluid disposed in the inner volume 633 between the first seal member 658 and the distal end portion 632 of the fluid reservoir 630 can be fluidically isolated from a volume outside the inner volume 633. Expanding further, the first seal member 658 prevents a flow of the bodily fluid in the proximal direction and the valve 639, being in the closed configuration, prevents a flow of the bodily fluid in the distal direction. Thus, the predetermined amount of bodily fluid is fluidically isolated from a volume outside the inner volume 633 of the fluid reservoir 630 defined between the first seal member 658 and the distal end portion 632.
As indicated by the arrow RR in
With the transfer device 600 in the third configuration, an external fluid source (not shown in
In some embodiments, user intervention maintains the transfer device 600 in the third configuration. Expanding further and as described above, the proximal movement of the fluid reservoir 630 is such that a portion of the force applied by the user (e.g., the physician, nurse, technician, or the like) to move the flow control mechanism 640 and fluid reservoir 630 is used to move the spring 649 to a compressed configuration. In such embodiments, the removal of the portion of the force would allow the spring 649 to expand and thereby move the fluid reservoir 630 in the distal direction. In other embodiments, a transfer device can include a catch, protrusion, latch or the like configured to maintain the spring in the compressed configuration.
While the transfer device 600 is shown in
As shown in
The housing 701 defines an inner volume 711 and a set of recess 710. The inner volume 711 is configured to receive at least a portion of the flow control mechanism 740. As shown in
The flow control mechanism 740 defines a first lumen 746, a second lumen 747, and a fluid reservoir 730. The first lumen 746 extends through a portion of the flow control mechanism 740 and is in fluid communication with the fluid reservoir 730. Similarly stated, the first lumen 746 extends through a portion of the flow control mechanism 740 to selectively place the fluid reservoir 730 in fluid communication with a volume substantially outside of the flow control mechanism 740, as described in further detail herein. As shown in
The flow control mechanism 740 has a circular cross-sectional shape such that when the flow control mechanism 740 is disposed within the inner volume 711, a portion of the flow control mechanism 740 forms a friction fit with the walls of the housing 701 defining the inner volume 711. For example, in some embodiments, the flow control mechanism 740 is formed from silicone and has a diameter larger than the diameter of the inner volume 711. In this manner, the diameter of the flow control mechanism 740 is reduced when the flow control mechanism 740 is disposed within the inner volume 711. Thus, the outer surface of the flow control mechanism 740 forms a friction fit with the inner surface of the walls defining the inner volume 711. In other embodiments, the flow control mechanism 740 can be any suitable elastomer configured to deform when disposed within the inner volume 711 of the housing 701.
In use, while in the first configuration, the cannula 724 of the cannula assembly 720 can be inserted into a portion of a patient to place the cannula 724 in fluid communication with, for example, a vein. In some embodiments, the cannula 724 can include a sharp point at a distal end such that the cannula 724 can pierce the portion of the patient. In other embodiments, the cannula assembly 720 can include a trocar (not shown) to facilitate the insertion of the cannula 724. As described above, the cannula assembly 720 is physically and fluidically coupled to the distal port 705 of the housing 701 such that when the cannula 724 is placed in fluid communication with the vein of the patient, the distal port 705 is placed in fluid communication with the vein.
As shown in
With a desired amount of bodily fluid transferred to the fluid reservoir 730, a user can engage the transfer device 700 to move the transfer device 700 from the first configuration to the second configuration. In some embodiments, the desired amount of bodily fluid transferred to the fluid reservoir 730 is a predetermined amount of fluid. For example, in some embodiments, the transfer device 700 can be configured to transfer bodily fluid until the pressure within the fluid reservoir 730 is equilibrium with the pressure of the portion of the body in which the cannula 724 is disposed (e.g., the vein). In some embodiments, at least a portion of the flow control mechanism 740 can be transparent to allow visualization of the bodily fluid flowing into the fluid reservoir 730. The flow control mechanism 740 can include indicators (e.g., 0.1 mL, 0.5 mL, 1 mL, 1.5 mL, 2 mL, 3 mL, 4 mL, 5 mL, etc. graduation marks) to the user can visualize the volume of bodily fluid that has been received in the fluid reservoir 730.
As shown in
When moved to the second configuration, the second lumen 747 defined by the flow control mechanism 740 is placed in fluid communication with the distal port 705 and the proximal port 706 of the housing 701. As described above, the proximal port 706 can be physically and fluidically coupled to an external fluid source (not shown in
While the flow control mechanism 740 is shown in
The housing 801 includes a proximal end portion 802, a distal end portion 803, and defines an inner volume 811. The inner volume 811 can receive at least a portion of the flow control mechanism 880 and the actuator 880, as further described herein. As shown in
The distal port 805 is configured to receive a distal cannula 817. The distal cannula 817 (e.g., a lumen defining cannula) is configured to be physically and fluidically coupled to a port 822 included in the cannula assembly 820. The port 822 can be any suitable port. For example, in some embodiments, the distal cannula 817 and the port 822 can be coupled via an adhesive or the like to fixedly couple the cannula assembly 820 to the housing 801. With the port 822 of the cannula assembly 820 coupled to the distal cannula 817 and with the distal cannula 817 coupled to the distal port 805, the distal port 805 is in fluid communication with a cannula 824 included in the cannula assembly 820, as further described herein.
The first proximal port 806 and the second proximal port 807 are configured to receive a first proximal cannula 812 and a second proximal cannula 814, respectively (e.g., lumen defining cannulas). Furthermore, the first proximal cannula 812 is physically and fluidically coupled to a first lock mechanism 813 that can further be physically and fluidically coupled to an external fluid reservoir (not shown in
Referring back to
The flow control mechanism 840 defines a first lumen 846 and a second lumen 847 and is disposed within the inner volume 821 defined by the housing 801. The flow control mechanism 840 defines a circular cross-sectional shape such that when the flow control mechanism 840 is disposed within the inner volume 821, a portion of the flow control mechanism 840 forms a friction fit with the walls of the housing 801 defining the inner volume 821, as described in detail above. The flow control mechanism 840 is operably coupled to and/or otherwise engages the actuator 880. For example, in some embodiments, the actuator mechanism 880 can be coupled to the flow control mechanism 840 via a mechanical fastener and/or adhesive. In other embodiments, the actuator mechanism 880 and the flow control mechanism 840 can be coupled in any suitable manner. Therefore, the flow control mechanism 840 is configured to move concurrently with the actuator mechanism 880 when the actuator mechanism 880 is rotated relative to the housing 801. In this manner, the flow control mechanism 840 can be moved to place the first lumen 846 or the second lumen 847 in fluid communication with the distal port 805, the first proximal port 806, and/or the second proximal port 807, as described in further detail herein.
In use, while in the first configuration, the cannula 824 of the cannula assembly 820 can be inserted into a portion of a patient to place the cannula 824 in fluid communication with, for example, a vein. In some embodiments, the cannula 824 can include a sharp point at a distal end such that the cannula 824 can pierce the portion of the patient. In other embodiments, the cannula assembly 820 can include a trocar (not shown) to facilitate the insertion of the cannula 824. As described above, the cannula assembly 820 is physically and fluidically coupled to the distal port 805 of the housing 801 such that when the cannula 824 is placed in fluid communication with the vein of the patient, the distal port 805 is placed in fluid communication with the vein.
Furthermore, a user (e.g., a physician, a nurse, a technician, or the like) can engage the transfer device 800 to physically and fluidically couple the first lock mechanism 813 to an external fluid reservoir (not shown). The external fluid reservoir can be any suitable reservoir. For example, in some embodiments, the external fluid reservoir can be a BacT/ALERT® SN or a BacT/ALERT® FA, manufactured by BIOMERIEUX, INC. In this manner, the external fluid reservoir can define a negative pressure within an inner volume of the reservoir. Therefore, when the flow control mechanism 840 is in the first configuration, a negative pressure differential introduces a suction force within the first proximal cannula 812, the first lumen 846 defined by the flow control mechanism 840, the distal cannula 817, and the cannula assembly 820. In this manner, the first proximal cannula 812, the first lumen 846 defined by the flow control mechanism 840, the distal cannula 817, and the cannula assembly 820 collectively define a fluid flow path configured to transfer a flow of a bodily fluid to the external fluid reservoir, as indicated by the arrow WW in
As shown in
With the desired amount of bodily fluid transferred to the external fluid reservoir, a user can engage the actuator mechanism 880 to move the transfer device 800 from the first configuration to the second configuration. In some embodiments, the desired amount of bodily fluid transferred to the external fluid reservoir is a predetermined amount of fluid. For example, in some embodiments, the transfer device 800 can be configured to transfer bodily fluid until the pressure within the external fluid reservoir is equilibrium with the pressure of the portion of the body in which the lumen-defining device is disposed (e.g., the vein), as described above. In some embodiments, at least a portion of the external fluid reservoir can be transparent to allow visualization of the bodily fluid flowing into the fluid reservoir. The external fluid reservoir can include indicators (e.g., 0.1 mL, 0.5 mL, 1 mL, 1.5 mL, 2 mL, 3 mL, 4 mL, 5 mL, etc. graduation marks to accommodate identification of diversion volumes ranging from just a few drops or centiliters of blood to a larger volumes) so the user can visualize the volume of bodily fluid that has been received in the external fluid reservoir.
The transfer device 800 can be moved from the first configuration to the second configuration by further moving the actuator mechanism 880 in the direction of the arrow XX in
With the transfer device in the second configuration, the second proximal lock mechanism 815 can be physically and fluidically coupled to the external fluid source (not shown in
With the cannula assembly in fluid communication with the patient, a predetermined volume of a bodily fluid is withdrawn from the patient, at 991. For example, in some embodiments, the fluid transfer device can include a flow control mechanism, such as those described above, that can be moved between a first configuration and a second configuration. In some embodiments, flow control mechanism can be configured to define a fluid flow path between, for example, the cannula assembly and a fluid reservoir included in and/or fluidically coupled to the fluid transfer device. In other embodiments, any portion of fluid transfer device can define at least a portion of the fluid flow path. For example, the fluid transfer device can include a housing or the like that can define at least a portion of the fluid flow path. Thus, the predetermined volume of the bodily fluid is transferred to the fluid reservoir, at 993. In some embodiments, the predetermined volume of the bodily fluid can include, for example, dermally residing microbes that were dislodged during, for example, the venipuncture event (e.g., inserting the cannula assembly into the patient).
Once the predetermined volume of bodily fluid is disposed in the fluid reservoir, the fluid transfer device is fluidically isolated from the fluid reservoir to sequester the predetermined volume of bodily fluid in the fluid reservoir, at 994. For example, in some embodiments, once the predetermined volume of bodily fluid is disposed in the fluid reservoir, the fluid transfer device can be physically and/or fluidically decoupled from the fluid reservoir. In other embodiments, the flow control mechanism (as described above) can be moved from the first configuration to the second configuration to fluidically isolate the fluid reservoir from a volume outside of the fluid reservoir. For example, in some embodiments, the flow control mechanism can define a lumen or the like that can define a fluid flow path between the cannula assembly and the fluid reservoir when in the first configuration. In such embodiments, the flow control mechanism can be transitioned (e.g., moved, rotated, and/or otherwise reconfigured) from the first configuration to the second configuration in which the lumen is removed from fluid communication with the cannula assembly and/or the fluid reservoir, thereby fluidically isolating the fluid reservoir from the cannula assembly. In some embodiments, the flow control mechanism can be configured to transition from the first configuration to the second configuration automatically once the predetermined volume of bodily fluid is disposed in the fluid reservoir.
With the fluid reservoir fluidically isolated from at least a portion of the fluid transfer device, fluid communication is established between the patient and a fluid source via the fluid transfer device, at 995. For example, in some embodiments, the fluid source can be operably coupled to the fluid transfer device to place the fluid source in fluid communication with at least a portion of the fluid transfer device. In some embodiments, the flow control mechanism (described above) can define a second lumen that can place the fluid source in fluid communication with the cannula assembly when in the second configuration. In other embodiments, with the fluid reservoir decoupled from the fluid transfer device that fluid source can be placed in fluid communication with the cannula assembly via any other portion of the fluid transfer device (e.g., a portion of a housing and/or the like). In this manner, a fluid can flow from the fluid source, through the fluid transfer device and into the patient. Moreover, by fluidically isolating the predetermined volume of bodily fluid the flow of fluid from the fluid source can be substantially free of contaminants such as, for example, the dermally residing microbes, as described above.
While various embodiments have been described above, it should be understood that they have been presented by way of example only, and not limitation. Where methods and steps described above indicate certain events occurring in certain order, those of ordinary skill in the art having the benefit of this disclosure would recognize that the ordering of certain steps may be modified and that such modifications are in accordance with the variations of the invention. Additionally, certain of the steps may be performed concurrently in a parallel process when possible, as well as performed sequentially as described above. Additionally, certain steps may be partially completed before proceeding to subsequent steps.
While various embodiments have been particularly shown and described, various changes in form and details may be made. For example, while the actuator 580 is shown and described with respect to
Although various embodiments have been described as having particular features and/or combinations of components, other embodiments are possible having any combination or sub-combination of any features and/or components from any of the embodiments described herein.
The specific configurations of the various components can also be varied. For example, the size and specific shape of the various components can be different from the embodiments shown, while still providing the functions as described herein. More specifically, the size and shape of the various components can be specifically selected for a desired rate of bodily fluid flow into a fluid reservoir or for a desired rate of parenteral fluid flow into the patient.
This application is a continuation of U.S. patent application Ser. No. 16/789,034, filed Feb. 12, 2020, now U.S. Pat. No. 11,890,452, entitled, “Systems and Methods for Delivering a Fluid to a Patient with Reduced Contamination,” which is a continuation of U.S. patent application Ser. No. 16/255,055, filed Jan. 23, 2019, now U.S. Pat. No. 10,596,315, entitled, “Systems and Methods for Delivering a Fluid to a Patient with Reduced Contamination,” which is a continuation of U.S. patent application Ser. No. 15/899,856, filed Feb. 20, 2018, now U.S. Pat. No. 10,220,139, entitled, “Systems and Methods for Delivering a Fluid to a Patient with Reduced Contamination,” which is a continuation of U.S. patent application Ser. No. 14/838,794, filed Aug. 28, 2015, now U.S. Pat. No. 9,931,466, entitled, “Systems and Methods for Delivering a Fluid to a Patient with Reduced Contamination,” which is a divisional of U.S. patent application Ser. No. 14/049,326, filed Oct. 9, 2013, now U.S. Pat. No. 9,149,576, entitled, “Systems and Methods for Delivering a Fluid to a Patient with Reduced Contamination,” which claims priority to and the benefit of U.S. Provisional Patent Application No. 61/712,468, filed Oct. 11, 2012, entitled, “Systems and Methods for Delivering a Fluid to a Patient with Reduced Contamination,” the disclosures of which are incorporated herein by reference in their entireties.
Number | Name | Date | Kind |
---|---|---|---|
2697435 | Benjamin | Dec 1954 | A |
2707953 | Ryan | May 1955 | A |
2847995 | Adams | Aug 1958 | A |
2876769 | Juan | Mar 1959 | A |
2952258 | Chandler | Sep 1960 | A |
2992974 | Belcove et al. | Jul 1961 | A |
3013557 | Pallotta | Dec 1961 | A |
3098016 | Sam et al. | Jul 1963 | A |
3382865 | Worrall, Jr. | May 1968 | A |
3405706 | Paul | Oct 1968 | A |
3467021 | Green, Jr. | Sep 1969 | A |
3467095 | Ross | Sep 1969 | A |
3494351 | Horn | Feb 1970 | A |
3494352 | Russo et al. | Feb 1970 | A |
3577980 | Cohen | May 1971 | A |
3596652 | Winkelman | Aug 1971 | A |
3604410 | Whitacre | Sep 1971 | A |
3635798 | Kirkham et al. | Jan 1972 | A |
3640267 | Hurtig et al. | Feb 1972 | A |
3648684 | Barnwell et al. | Mar 1972 | A |
3680558 | Kapelowitz | Aug 1972 | A |
3696806 | Sausse | Oct 1972 | A |
3730168 | McWhorter | May 1973 | A |
3741197 | Sanz et al. | Jun 1973 | A |
3777773 | Tolbert | Dec 1973 | A |
3779383 | Ayres | Dec 1973 | A |
3803810 | Rosenberg | Apr 1974 | A |
3817240 | Ayres | Jun 1974 | A |
3831602 | Broadwin | Aug 1974 | A |
3834372 | Turney | Sep 1974 | A |
3835835 | Thompson et al. | Sep 1974 | A |
3848579 | Villa | Nov 1974 | A |
3848581 | Cinqualbre et al. | Nov 1974 | A |
3859998 | Thomas et al. | Jan 1975 | A |
3874367 | Ayres | Apr 1975 | A |
3886930 | Ryan | Jun 1975 | A |
3890203 | Mehl | Jun 1975 | A |
3890968 | Pierce et al. | Jun 1975 | A |
3937211 | Merten | Feb 1976 | A |
3943917 | Johansen | Mar 1976 | A |
3945380 | Dabney et al. | Mar 1976 | A |
3960139 | Bailey | Jun 1976 | A |
3978846 | Bailey | Sep 1976 | A |
3996923 | Guerra | Dec 1976 | A |
4056101 | Geissler et al. | Nov 1977 | A |
4057050 | Sarstedt | Nov 1977 | A |
4062360 | Bentley | Dec 1977 | A |
4063460 | Svensson | Dec 1977 | A |
4077395 | Woolner | Mar 1978 | A |
4106491 | Guerra | Aug 1978 | A |
4106497 | Percarpio | Aug 1978 | A |
4133304 | Bailey | Jan 1979 | A |
4133863 | Koenig | Jan 1979 | A |
4150089 | Linet | Apr 1979 | A |
4154229 | Nugent | May 1979 | A |
4166450 | Abramson | Sep 1979 | A |
4190426 | Ruschke | Feb 1980 | A |
4193400 | Loveless et al. | Mar 1980 | A |
4202764 | Afflerbaugh et al. | May 1980 | A |
4207870 | Eldridge | Jun 1980 | A |
4210173 | Choksi et al. | Jul 1980 | A |
4212308 | Percarpio | Jul 1980 | A |
4226236 | Genese | Oct 1980 | A |
4238207 | Ruschke | Dec 1980 | A |
4257416 | Prager | Mar 1981 | A |
4275730 | Hussein | Jun 1981 | A |
4298358 | Ruschke | Nov 1981 | A |
4312362 | Kaufman | Jan 1982 | A |
4317456 | Percarpio | Mar 1982 | A |
4327746 | Feaster | May 1982 | A |
4340067 | Rattenborg | Jul 1982 | A |
4340068 | Kaufman | Jul 1982 | A |
4349035 | Thomas et al. | Sep 1982 | A |
4354507 | Raitto | Oct 1982 | A |
4370987 | Bazell et al. | Feb 1983 | A |
4373535 | Martell | Feb 1983 | A |
4398544 | Nugent et al. | Aug 1983 | A |
4411275 | Raitto | Oct 1983 | A |
4412548 | Hoch | Nov 1983 | A |
4416290 | Lutkowski | Nov 1983 | A |
4416291 | Kaufman | Nov 1983 | A |
4425235 | Cornell et al. | Jan 1984 | A |
4436098 | Kaufman | Mar 1984 | A |
4444203 | Engelman | Apr 1984 | A |
4459997 | Sarstedt | Jul 1984 | A |
4496458 | Lee | Jan 1985 | A |
4509534 | Tassin, Jr. | Apr 1985 | A |
4581014 | Millerd et al. | Apr 1986 | A |
4608996 | Brown | Sep 1986 | A |
4626248 | Scheller | Dec 1986 | A |
4654027 | Dragan et al. | Mar 1987 | A |
4657027 | Paulsen | Apr 1987 | A |
4657160 | Woods et al. | Apr 1987 | A |
4673386 | Gordon | Jun 1987 | A |
4676256 | Golden | Jun 1987 | A |
4679571 | Frankel et al. | Jul 1987 | A |
4690154 | Woodford et al. | Sep 1987 | A |
4699612 | Hamacher | Oct 1987 | A |
4703763 | McAlister et al. | Nov 1987 | A |
4705497 | Shitaokoshi et al. | Nov 1987 | A |
4714461 | Gabel | Dec 1987 | A |
4715854 | Vaillancourt | Dec 1987 | A |
4772273 | Alchas | Sep 1988 | A |
4838855 | Lynn | Jun 1989 | A |
4865583 | Tu | Sep 1989 | A |
4879098 | Oberhardt et al. | Nov 1989 | A |
4886072 | Percarpio et al. | Dec 1989 | A |
4890627 | Haber et al. | Jan 1990 | A |
4904240 | Hoover | Feb 1990 | A |
4936315 | Lineback | Jun 1990 | A |
4980297 | Haynes et al. | Dec 1990 | A |
4988339 | Vadher | Jan 1991 | A |
5027827 | Cody et al. | Jul 1991 | A |
5032116 | Peterson et al. | Jul 1991 | A |
5032288 | Columbus et al. | Jul 1991 | A |
5035688 | Inui | Jul 1991 | A |
5045185 | Ohnaka et al. | Sep 1991 | A |
5052403 | Haber et al. | Oct 1991 | A |
5054498 | Melet | Oct 1991 | A |
5066284 | Mersch et al. | Nov 1991 | A |
5084034 | Zanotti | Jan 1992 | A |
5097842 | Bonn | Mar 1992 | A |
5100394 | Dudar et al. | Mar 1992 | A |
5108927 | Dorn | Apr 1992 | A |
5116323 | Kreuzer et al. | May 1992 | A |
5122129 | Olson et al. | Jun 1992 | A |
5126054 | Matkovich | Jun 1992 | A |
5135489 | Jepson et al. | Aug 1992 | A |
5147329 | Brannon | Sep 1992 | A |
5222502 | Kurose | Jun 1993 | A |
5269317 | Bennett | Dec 1993 | A |
5330464 | Mathias et al. | Jul 1994 | A |
5334162 | Harris | Aug 1994 | A |
5354537 | Moreno | Oct 1994 | A |
5360011 | McCallister | Nov 1994 | A |
5372143 | Bernes et al. | Dec 1994 | A |
5395339 | Talonn et al. | Mar 1995 | A |
5417673 | Gordon | May 1995 | A |
5429610 | Vaillancourt | Jul 1995 | A |
5431811 | Tusini et al. | Jul 1995 | A |
5439022 | Summers et al. | Aug 1995 | A |
5439450 | Haedt | Aug 1995 | A |
5450856 | Norris | Sep 1995 | A |
5451321 | Matkovich | Sep 1995 | A |
5454786 | Harris | Oct 1995 | A |
5466228 | Evans | Nov 1995 | A |
5472605 | Zuk, Jr. | Dec 1995 | A |
5485854 | Hollister | Jan 1996 | A |
5507299 | Roland | Apr 1996 | A |
5520193 | Suzuki et al. | May 1996 | A |
5522804 | Lynn | Jun 1996 | A |
5573510 | Isaacson | Nov 1996 | A |
5573951 | Gombrich et al. | Nov 1996 | A |
5575777 | Cover et al. | Nov 1996 | A |
5577513 | Van Vlasselaer | Nov 1996 | A |
5603700 | Daneshvar | Feb 1997 | A |
5632906 | Ishida et al. | May 1997 | A |
5634893 | Rishton | Jun 1997 | A |
5649912 | Peterson | Jul 1997 | A |
5658271 | Loubser | Aug 1997 | A |
5685846 | Michaels, Jr. | Nov 1997 | A |
5691486 | Behringer et al. | Nov 1997 | A |
5749857 | Cuppy | May 1998 | A |
5759160 | Neese et al. | Jun 1998 | A |
5762633 | Whisson | Jun 1998 | A |
5772608 | Dhas | Jun 1998 | A |
5785682 | Grabenkort | Jul 1998 | A |
5811658 | Van Driel et al. | Sep 1998 | A |
5824001 | Erskine | Oct 1998 | A |
5857983 | Douglas et al. | Jan 1999 | A |
5865803 | Major | Feb 1999 | A |
5865812 | Correia | Feb 1999 | A |
5871699 | Ruggeri | Feb 1999 | A |
5873841 | Brannon | Feb 1999 | A |
5876926 | Beecham | Mar 1999 | A |
5882318 | Boyde | Mar 1999 | A |
5911705 | Howell | Jun 1999 | A |
5922551 | Durbin et al. | Jul 1999 | A |
RE36273 | Brannon | Aug 1999 | E |
5947932 | Desecki et al. | Sep 1999 | A |
5961472 | Swendson et al. | Oct 1999 | A |
5971956 | Epstein | Oct 1999 | A |
5980830 | Savage et al. | Nov 1999 | A |
6001307 | Naka et al. | Dec 1999 | A |
6010633 | Zuk, Jr. et al. | Jan 2000 | A |
6013037 | Brannon | Jan 2000 | A |
6016712 | Warden et al. | Jan 2000 | A |
6050957 | Desch | Apr 2000 | A |
6106509 | Loubser | Aug 2000 | A |
6126643 | Vaillancouert | Oct 2000 | A |
6159164 | Neese et al. | Dec 2000 | A |
6171493 | Zia et al. | Jan 2001 | B1 |
6190855 | Herman et al. | Feb 2001 | B1 |
6210909 | Guirguis | Apr 2001 | B1 |
6224561 | Swendson et al. | May 2001 | B1 |
6254581 | Scott | Jul 2001 | B1 |
6296020 | McNeely et al. | Oct 2001 | B1 |
6306614 | Romaschin et al. | Oct 2001 | B1 |
6325975 | Naka et al. | Dec 2001 | B1 |
6328726 | Ishida et al. | Dec 2001 | B1 |
6355023 | Roth et al. | Mar 2002 | B1 |
6364847 | Shulze et al. | Apr 2002 | B1 |
6364890 | Lum et al. | Apr 2002 | B1 |
6368306 | Koska | Apr 2002 | B1 |
6387086 | Mathias et al. | May 2002 | B2 |
6398743 | Halseth et al. | Jun 2002 | B1 |
6403381 | Mann et al. | Jun 2002 | B1 |
6440725 | Pourahmadi et al. | Aug 2002 | B1 |
6478775 | Galt et al. | Nov 2002 | B1 |
6506182 | Estabrook et al. | Jan 2003 | B2 |
6511439 | Tabata et al. | Jan 2003 | B1 |
6520948 | Mathias et al. | Feb 2003 | B1 |
6569117 | Ziv et al. | May 2003 | B1 |
6592555 | Wen-Pi et al. | Jul 2003 | B1 |
6592613 | Ishida et al. | Jul 2003 | B1 |
6626884 | Dillon et al. | Sep 2003 | B1 |
6629959 | Kuracina et al. | Oct 2003 | B2 |
6638252 | Moulton et al. | Oct 2003 | B2 |
6638263 | Theeuwes et al. | Oct 2003 | B1 |
6648835 | Shemesh | Nov 2003 | B1 |
6692479 | Kraus et al. | Feb 2004 | B2 |
6695004 | Raybuck | Feb 2004 | B1 |
6712963 | Schick | Mar 2004 | B2 |
6716187 | Jorgensen et al. | Apr 2004 | B1 |
6716396 | Anderson et al. | Apr 2004 | B1 |
6733433 | Fell | May 2004 | B1 |
6736783 | Blake et al. | May 2004 | B2 |
6746420 | Prestidge et al. | Jun 2004 | B1 |
6772513 | Frye-Mason et al. | Aug 2004 | B1 |
6843775 | Hyun | Jan 2005 | B2 |
6860871 | Kuracina et al. | Mar 2005 | B2 |
6905483 | Newby et al. | Jun 2005 | B2 |
6913580 | Stone | Jul 2005 | B2 |
6945948 | Bainbridge et al. | Sep 2005 | B2 |
7044941 | Mathias et al. | May 2006 | B2 |
7052603 | Schick | May 2006 | B2 |
7055401 | Prybella et al. | Jun 2006 | B2 |
7087047 | Kraus et al. | Aug 2006 | B2 |
7141097 | Leahey | Nov 2006 | B2 |
7211074 | Sansoucy | May 2007 | B2 |
7241281 | Coelho et al. | Jul 2007 | B2 |
7261707 | Frezza et al. | Aug 2007 | B2 |
7264608 | Bischof et al. | Sep 2007 | B2 |
7306736 | Collins et al. | Dec 2007 | B2 |
7314452 | Madonia | Jan 2008 | B2 |
7316662 | Delnevo et al. | Jan 2008 | B2 |
7335188 | Graf | Feb 2008 | B2 |
7351228 | Keane et al. | Apr 2008 | B2 |
7384416 | Goudaliez et al. | Jun 2008 | B2 |
7435231 | Mathias et al. | Oct 2008 | B2 |
7461671 | Ehwald et al. | Dec 2008 | B2 |
7479131 | Mathias et al. | Jan 2009 | B2 |
7544324 | Tung et al. | Jun 2009 | B2 |
7614857 | Fuechslin et al. | Nov 2009 | B2 |
7615033 | Leong | Nov 2009 | B2 |
7618407 | Demay et al. | Nov 2009 | B2 |
7648491 | Rogers | Jan 2010 | B2 |
7666166 | Emmert et al. | Feb 2010 | B1 |
7744573 | Gordon et al. | Jun 2010 | B2 |
7766879 | Tan et al. | Aug 2010 | B2 |
7896817 | Garrison | Mar 2011 | B2 |
7914508 | Engstrom | Mar 2011 | B2 |
7963950 | Madonia | Jun 2011 | B2 |
8070725 | Christensen | Dec 2011 | B2 |
8109157 | Kanayama et al. | Feb 2012 | B2 |
RE43283 | Ishida et al. | Mar 2012 | E |
8197420 | Patton | Jun 2012 | B2 |
8206318 | Uchiyama et al. | Jun 2012 | B2 |
8231546 | Patton | Jul 2012 | B2 |
8282605 | Tan et al. | Oct 2012 | B2 |
8287499 | Miyasaka | Oct 2012 | B2 |
8337418 | Patton | Dec 2012 | B2 |
8349254 | Hoshino et al. | Jan 2013 | B2 |
8356644 | Chong et al. | Jan 2013 | B2 |
8377040 | Burkholz et al. | Feb 2013 | B2 |
8382712 | Kim | Feb 2013 | B2 |
8383044 | Davis et al. | Feb 2013 | B2 |
8412300 | Sonderegger | Apr 2013 | B2 |
8523826 | Layton, Jr. | Sep 2013 | B2 |
8535241 | Bullington et al. | Sep 2013 | B2 |
8540663 | Davey et al. | Sep 2013 | B2 |
8568371 | Siopes et al. | Oct 2013 | B2 |
8574203 | Stout et al. | Nov 2013 | B2 |
8603009 | Tan et al. | Dec 2013 | B2 |
8647286 | Patton | Feb 2014 | B2 |
8679063 | Stout et al. | Mar 2014 | B2 |
8747779 | Sprague et al. | Jun 2014 | B2 |
8772046 | Fraden et al. | Jul 2014 | B2 |
8795198 | Tan et al. | Aug 2014 | B2 |
8827958 | Bierman et al. | Sep 2014 | B2 |
8864684 | Bullington et al. | Oct 2014 | B2 |
8876734 | Patton | Nov 2014 | B2 |
8992505 | Thorne, Jr. et al. | Mar 2015 | B2 |
9022950 | Bullington et al. | May 2015 | B2 |
9022951 | Bullington et al. | May 2015 | B2 |
9060724 | Bullington et al. | Jun 2015 | B2 |
9060725 | Bullington et al. | Jun 2015 | B2 |
9138572 | Zeytoonian et al. | Sep 2015 | B2 |
9149576 | Bullington et al. | Oct 2015 | B2 |
9155495 | Bullington et al. | Oct 2015 | B2 |
9204864 | Bullington et al. | Dec 2015 | B2 |
9233208 | Tekeste | Jan 2016 | B2 |
RE45896 | Stout et al. | Feb 2016 | E |
9314201 | Burkholz et al. | Apr 2016 | B2 |
9320459 | Chin et al. | Apr 2016 | B2 |
9855001 | Patton | Jan 2018 | B2 |
9855002 | Patton | Jan 2018 | B2 |
9855386 | Close et al. | Jan 2018 | B2 |
9861306 | Patton | Jan 2018 | B2 |
9872645 | Patton | Jan 2018 | B2 |
9877674 | Holmes et al. | Jan 2018 | B2 |
9877675 | Baid | Jan 2018 | B2 |
9895092 | Burkholz | Feb 2018 | B2 |
9931466 | Bullington et al. | Apr 2018 | B2 |
9950084 | Bullington et al. | Apr 2018 | B2 |
9999383 | Bullington et al. | Jun 2018 | B2 |
10022530 | Tekeste | Jul 2018 | B2 |
10028687 | Patton | Jul 2018 | B2 |
10028688 | Patton | Jul 2018 | B2 |
10028689 | Patton | Jul 2018 | B2 |
10039483 | Bullington et al. | Aug 2018 | B2 |
10045724 | Patton | Aug 2018 | B2 |
10052053 | Patton | Aug 2018 | B2 |
10080516 | Ellis et al. | Sep 2018 | B2 |
10206613 | Bullington et al. | Feb 2019 | B2 |
10220139 | Bullington et al. | Mar 2019 | B2 |
10251590 | Bullington et al. | Apr 2019 | B2 |
10265007 | Bullington et al. | Apr 2019 | B2 |
10292633 | Bullington et al. | May 2019 | B2 |
10299713 | Patton | May 2019 | B2 |
10433779 | Bullington et al. | Oct 2019 | B2 |
10596315 | Bullington et al. | Mar 2020 | B2 |
10624977 | Bullington et al. | Apr 2020 | B2 |
10736554 | Bullington et al. | Aug 2020 | B2 |
10772548 | Bullington et al. | Sep 2020 | B2 |
10827964 | Rogers et al. | Nov 2020 | B2 |
10856791 | McHale et al. | Dec 2020 | B2 |
10881343 | Bullington et al. | Jan 2021 | B2 |
10888262 | Russ et al. | Jan 2021 | B2 |
10912506 | Bullington et al. | Feb 2021 | B2 |
11076787 | Bullington et al. | Aug 2021 | B2 |
11234626 | Bullington et al. | Feb 2022 | B2 |
11259727 | Bullington et al. | Mar 2022 | B2 |
11311218 | Bullington et al. | Apr 2022 | B2 |
11317838 | Bullington et al. | May 2022 | B2 |
11318459 | Shi et al. | May 2022 | B2 |
11395611 | Bullington et al. | Jul 2022 | B2 |
11395612 | Bullington et al. | Jul 2022 | B2 |
11419531 | Bullington et al. | Aug 2022 | B2 |
11529081 | Bullington et al. | Dec 2022 | B2 |
11589786 | Bullington et al. | Feb 2023 | B2 |
11607159 | Bullington et al. | Mar 2023 | B2 |
11653863 | Bullington et al. | May 2023 | B2 |
11660030 | Bullington et al. | May 2023 | B2 |
11737693 | Bullington et al. | Aug 2023 | B2 |
11786155 | Bullington et al. | Oct 2023 | B2 |
11819329 | Bullington et al. | Nov 2023 | B2 |
11857321 | Bullington et al. | Jan 2024 | B2 |
11890452 | Bullington et al. | Feb 2024 | B2 |
11903709 | Bullington et al. | Feb 2024 | B2 |
11903710 | Bullington et al. | Feb 2024 | B2 |
11998332 | Bullington et al. | Jun 2024 | B2 |
20020002349 | Flaherty et al. | Jan 2002 | A1 |
20020004647 | Leong | Jan 2002 | A1 |
20020107469 | Bolan et al. | Aug 2002 | A1 |
20020183651 | Hyun | Dec 2002 | A1 |
20020193751 | Theeuwes et al. | Dec 2002 | A1 |
20030013991 | Stone | Jan 2003 | A1 |
20030055381 | Wilkinson | Mar 2003 | A1 |
20030069543 | Carpenter et al. | Apr 2003 | A1 |
20030105414 | Leong | Jun 2003 | A1 |
20030208151 | Kraus | Nov 2003 | A1 |
20040000309 | Alston | Jan 2004 | A1 |
20040009542 | Dumont et al. | Jan 2004 | A1 |
20040010228 | Swenson et al. | Jan 2004 | A1 |
20040054283 | Corey et al. | Mar 2004 | A1 |
20040054333 | Theeuwes et al. | Mar 2004 | A1 |
20040073171 | Rogers et al. | Apr 2004 | A1 |
20040127816 | Galvao | Jul 2004 | A1 |
20040147855 | Marsden | Jul 2004 | A1 |
20050004524 | Newby et al. | Jan 2005 | A1 |
20050054949 | McKinnon et al. | Mar 2005 | A1 |
20050131344 | Godaire | Jun 2005 | A1 |
20050148993 | Mathias et al. | Jul 2005 | A1 |
20050154368 | Lim et al. | Jul 2005 | A1 |
20050161112 | Ehwald et al. | Jul 2005 | A1 |
20050199077 | Prybella et al. | Sep 2005 | A1 |
20050240161 | Crawford | Oct 2005 | A1 |
20050245885 | Brown | Nov 2005 | A1 |
20050273019 | Conway et al. | Dec 2005 | A1 |
20050277848 | Graf | Dec 2005 | A1 |
20050281713 | Hampsch et al. | Dec 2005 | A1 |
20060018790 | Naka et al. | Jan 2006 | A1 |
20060111667 | Matsuura et al. | May 2006 | A1 |
20060155212 | Madonia | Jul 2006 | A1 |
20060251622 | Suzuki et al. | Nov 2006 | A1 |
20060287639 | Sharp | Dec 2006 | A1 |
20070083162 | O'Reagan et al. | Apr 2007 | A1 |
20070088279 | Shue et al. | Apr 2007 | A1 |
20070100250 | Kline | May 2007 | A1 |
20070119508 | West et al. | May 2007 | A1 |
20070191716 | Goldberger et al. | Aug 2007 | A1 |
20070232956 | Harman et al. | Oct 2007 | A1 |
20070287948 | Sakiewicz | Dec 2007 | A1 |
20080086085 | Brown | Apr 2008 | A1 |
20080108954 | Mathias et al. | May 2008 | A1 |
20080114304 | Nalesso et al. | May 2008 | A1 |
20080167577 | Weilbacher et al. | Jul 2008 | A1 |
20080185056 | Diodati et al. | Aug 2008 | A1 |
20080200837 | Frazier et al. | Aug 2008 | A1 |
20080254471 | Bordano | Oct 2008 | A1 |
20080255523 | Grinberg | Oct 2008 | A1 |
20080312576 | McKinnon et al. | Dec 2008 | A1 |
20080319346 | Crawford et al. | Dec 2008 | A1 |
20090076441 | Sebban | Mar 2009 | A1 |
20090173685 | Imai et al. | Jul 2009 | A1 |
20090177117 | Amano et al. | Jul 2009 | A1 |
20090192447 | Andersen et al. | Jul 2009 | A1 |
20090227896 | Alvin Tan et al. | Sep 2009 | A1 |
20090301317 | Andrews | Dec 2009 | A1 |
20090306601 | Shaw et al. | Dec 2009 | A1 |
20100010372 | Brown et al. | Jan 2010 | A1 |
20100042048 | Christensen | Feb 2010 | A1 |
20100057004 | Christensen et al. | Mar 2010 | A1 |
20100094171 | Conway et al. | Apr 2010 | A1 |
20100152681 | Mathias | Jun 2010 | A1 |
20100185134 | Houwen et al. | Jul 2010 | A1 |
20100234768 | Uchiyama et al. | Sep 2010 | A1 |
20100240964 | Sterling et al. | Sep 2010 | A1 |
20100252118 | Fraden et al. | Oct 2010 | A1 |
20100255589 | Saiki et al. | Oct 2010 | A1 |
20100268118 | Schweiger | Oct 2010 | A1 |
20100286513 | Pollard, Jr. et al. | Nov 2010 | A1 |
20100298671 | Asakura et al. | Nov 2010 | A1 |
20110009717 | Davis et al. | Jan 2011 | A1 |
20110046602 | Grimm et al. | Feb 2011 | A1 |
20110092856 | Freeman et al. | Apr 2011 | A1 |
20110125058 | Levinson et al. | May 2011 | A1 |
20110306856 | Rule et al. | Dec 2011 | A1 |
20110306899 | Brown et al. | Dec 2011 | A1 |
20110313318 | Rule et al. | Dec 2011 | A1 |
20120004619 | Stephens et al. | Jan 2012 | A1 |
20120016266 | Burkholz | Jan 2012 | A1 |
20120017999 | Velschow | Jan 2012 | A1 |
20120035540 | Ferren et al. | Feb 2012 | A1 |
20120215131 | Patton | Aug 2012 | A1 |
20120226239 | Green | Sep 2012 | A1 |
20120265099 | Goodnow, II et al. | Oct 2012 | A1 |
20120265128 | Kolln | Oct 2012 | A1 |
20120277697 | Haghgooie et al. | Nov 2012 | A1 |
20120323142 | Allen et al. | Dec 2012 | A1 |
20130023792 | Markey et al. | Jan 2013 | A1 |
20130085514 | Lee et al. | Apr 2013 | A1 |
20130158506 | Harris et al. | Jun 2013 | A1 |
20130289420 | Pfeiffer et al. | Oct 2013 | A1 |
20130295602 | Fowler et al. | Nov 2013 | A1 |
20140008366 | Genosar | Jan 2014 | A1 |
20140051062 | Vanapalli et al. | Feb 2014 | A1 |
20140066880 | Prince et al. | Mar 2014 | A1 |
20140128775 | Andreae et al. | May 2014 | A1 |
20140155782 | Bullington et al. | Jun 2014 | A1 |
20140188002 | Close et al. | Jul 2014 | A1 |
20140221873 | Hayakawa et al. | Aug 2014 | A1 |
20140276039 | Cowan et al. | Sep 2014 | A1 |
20140305196 | Ellis et al. | Oct 2014 | A1 |
20150011847 | Hayden | Jan 2015 | A1 |
20150018715 | Walterspiel | Jan 2015 | A1 |
20150025454 | Wetzel et al. | Jan 2015 | A1 |
20150025455 | Shetty et al. | Jan 2015 | A1 |
20150025456 | Shetty et al. | Jan 2015 | A1 |
20150073304 | Millerd | Mar 2015 | A1 |
20150314105 | Gasparyan et al. | Nov 2015 | A1 |
20160008579 | Burkholz et al. | Jan 2016 | A1 |
20160038684 | Lum et al. | Feb 2016 | A1 |
20160081606 | Russ et al. | Mar 2016 | A1 |
20160174888 | Berthier et al. | Jun 2016 | A1 |
20160213294 | Patton | Jul 2016 | A1 |
20160367177 | Edelhauser et al. | Dec 2016 | A1 |
20170059552 | Campton et al. | Mar 2017 | A1 |
20170071519 | Gelfand et al. | Mar 2017 | A1 |
20170153165 | Nwadigo | Jun 2017 | A1 |
20170276679 | Chapman et al. | Sep 2017 | A1 |
20170327867 | Dohale et al. | Nov 2017 | A1 |
20180160958 | Baid | Jun 2018 | A1 |
20180242890 | Chickering, III et al. | Aug 2018 | A1 |
20180353117 | Bullington et al. | Dec 2018 | A1 |
20190000367 | Lundquist et al. | Jan 2019 | A1 |
20190049442 | Guirguis | Feb 2019 | A1 |
20190150818 | Bullington et al. | May 2019 | A1 |
20190175085 | Bullington et al. | Jun 2019 | A1 |
20190209066 | Bullington et al. | Jul 2019 | A1 |
20190365303 | Bullington et al. | Dec 2019 | A1 |
20200060595 | Bullington et al. | Feb 2020 | A1 |
20200060596 | Patton | Feb 2020 | A1 |
20200215211 | Bullington et al. | Jul 2020 | A1 |
20200253524 | Bullington et al. | Aug 2020 | A1 |
20200289039 | Bullington et al. | Sep 2020 | A1 |
20210008280 | Bullington et al. | Jan 2021 | A1 |
20210169387 | Bullington et al. | Jun 2021 | A1 |
20210186392 | Bullington et al. | Jun 2021 | A1 |
20210361206 | Bullington et al. | Nov 2021 | A1 |
20210361207 | Rogers et al. | Nov 2021 | A1 |
20220151525 | Bullington et al. | May 2022 | A1 |
20220151526 | Bullington et al. | May 2022 | A1 |
20220151527 | Bullington et al. | May 2022 | A1 |
20220175284 | Bullington et al. | Jun 2022 | A1 |
20220183600 | Bullington et al. | Jun 2022 | A1 |
20220218248 | Bullington et al. | Jul 2022 | A1 |
20220218249 | Bullington et al. | Jul 2022 | A1 |
20220218250 | Bullington et al. | Jul 2022 | A1 |
20220287604 | Armstrong et al. | Sep 2022 | A1 |
20220304600 | Hammer | Sep 2022 | A1 |
20220304601 | Bullington et al. | Sep 2022 | A1 |
20220304664 | Hammer | Sep 2022 | A1 |
20220361786 | Bullington et al. | Nov 2022 | A1 |
20220369971 | Bullington et al. | Nov 2022 | A1 |
20220369972 | Bullington et al. | Nov 2022 | A1 |
20230172502 | Bullington et al. | Jun 2023 | A1 |
20230190157 | Bullington et al. | Jun 2023 | A1 |
20230240571 | Bullington et al. | Aug 2023 | A1 |
20230248281 | Bullington et al. | Aug 2023 | A1 |
20230363674 | Bullington et al. | Nov 2023 | A1 |
20240008780 | Bullington et al. | Jan 2024 | A1 |
20240041369 | Bullington et al. | Feb 2024 | A1 |
20240041370 | Bullington et al. | Feb 2024 | A1 |
20240065590 | Bullington et al. | Feb 2024 | A1 |
20240138734 | Bullington et al. | May 2024 | A1 |
20240164670 | Patton | May 2024 | A1 |
Number | Date | Country |
---|---|---|
310345 | Sep 1973 | AT |
736156 | Jul 2001 | AU |
112012025546 | Jun 2016 | BR |
86103696 | Jan 1987 | CN |
2115767 | Sep 1992 | CN |
1713928 | Dec 2005 | CN |
1784186 | Jun 2006 | CN |
1901955 | Jan 2007 | CN |
2907683 | Jun 2007 | CN |
101060871 | Oct 2007 | CN |
101309641 | Nov 2008 | CN |
101352357 | Jan 2009 | CN |
101437450 | May 2009 | CN |
101631498 | Jan 2010 | CN |
101676001 | Mar 2010 | CN |
101801445 | Aug 2010 | CN |
102548524 | Jul 2012 | CN |
102971040 | Mar 2013 | CN |
103027727 | Apr 2013 | CN |
101626803 | Aug 2013 | CN |
103477201 | Dec 2013 | CN |
105090005 | Nov 2015 | CN |
105612346 | May 2016 | CN |
107736901 | Feb 2018 | CN |
7203008 | May 1972 | DE |
2203858 | May 1973 | DE |
2541494 | Mar 1977 | DE |
2203858 | Oct 1977 | DE |
2946660 | May 1981 | DE |
3403957 | Aug 1985 | DE |
29913417 | Dec 2000 | DE |
10038026 | Feb 2001 | DE |
10134913 | Feb 2003 | DE |
10134913 | Jun 2003 | DE |
10243129 | Apr 2004 | DE |
102009057792 | Aug 2016 | DE |
0207304 | Jan 1987 | EP |
0448795 | Oct 1991 | EP |
0208053 | Dec 1991 | EP |
0329786 | Jan 1993 | EP |
0486059 | Jan 1997 | EP |
1144026 | Jul 2004 | EP |
1980204 | Oct 2008 | EP |
2254472 | Dec 2010 | EP |
1381438 | May 2012 | EP |
1487369 | May 2017 | EP |
2986218 | Dec 2017 | EP |
2178585 | Apr 2021 | EP |
2110516 | Jun 1972 | FR |
2691364 | Aug 1999 | FR |
2833175 | May 2004 | FR |
2851167 | Oct 2005 | FR |
1506449 | Apr 1978 | GB |
1562686 | Mar 1980 | GB |
904353 | Oct 1991 | IE |
128709 | Sep 2004 | IL |
S5397289 | Aug 1978 | JP |
S5789869 | Jun 1982 | JP |
S6458241 | Mar 1989 | JP |
H0363570 | Mar 1991 | JP |
H06500403 | Jan 1994 | JP |
H0716219 | Jan 1995 | JP |
H0910302 | Jan 1997 | JP |
H10211274 | Aug 1998 | JP |
H1156821 | Mar 1999 | JP |
H1176397 | Mar 1999 | JP |
2001159630 | Jun 2001 | JP |
2001276181 | Oct 2001 | JP |
3231086 | Nov 2001 | JP |
2002116201 | Apr 2002 | JP |
2005237617 | Sep 2005 | JP |
2006026327 | Feb 2006 | JP |
3813974 | Aug 2006 | JP |
2007175534 | Jul 2007 | JP |
2008149076 | Jul 2008 | JP |
2008206734 | Sep 2008 | JP |
4382322 | Dec 2009 | JP |
2010514501 | May 2010 | JP |
4573538 | Nov 2010 | JP |
4861649 | Jan 2012 | JP |
4869910 | Feb 2012 | JP |
5620541 | Nov 2014 | JP |
2015014552 | Jan 2015 | JP |
2016523591 | Aug 2016 | JP |
5997760 | Sep 2016 | JP |
2016527939 | Sep 2016 | JP |
6194415 | Sep 2017 | JP |
2018525191 | Sep 2018 | JP |
20120030087 | Mar 2012 | KR |
101134279 | Apr 2012 | KR |
200528066 | Sep 2005 | TW |
WO-8605568 | Sep 1986 | WO |
WO-9004351 | May 1990 | WO |
WO-9118632 | Dec 1991 | WO |
WO-9216144 | Oct 1992 | WO |
WO-9407415 | Apr 1994 | WO |
WO-9412093 | Jun 1994 | WO |
WO-9415665 | Jul 1994 | WO |
WO-9511712 | May 1995 | WO |
WO-9516395 | Jun 1995 | WO |
WO-9521639 | Aug 1995 | WO |
WO-9524176 | Sep 1995 | WO |
WO-9621853 | Jul 1996 | WO |
WO-9718845 | May 1997 | WO |
WO-9846136 | Oct 1998 | WO |
WO-9913925 | Mar 1999 | WO |
WO-9948425 | Sep 1999 | WO |
WO-9955232 | Nov 1999 | WO |
WO-0040291 | Jul 2000 | WO |
WO-0041624 | Jul 2000 | WO |
WO-0108546 | Feb 2001 | WO |
WO-0191829 | Dec 2001 | WO |
WO-0245813 | Jun 2002 | WO |
WO-02051520 | Jul 2002 | WO |
WO-03008012 | Jan 2003 | WO |
WO-03041767 | May 2003 | WO |
WO-03047660 | Jun 2003 | WO |
WO-03078964 | Sep 2003 | WO |
WO-03085395 | Oct 2003 | WO |
WO-2004103565 | Dec 2004 | WO |
WO-2005068011 | Jul 2005 | WO |
WO-2006031500 | Mar 2006 | WO |
WO-2007033319 | Mar 2007 | WO |
WO-2008028165 | Mar 2008 | WO |
WO-2008077047 | Jun 2008 | WO |
WO-2008101025 | Aug 2008 | WO |
WO-2009094345 | Jul 2009 | WO |
WO-2009113999 | Sep 2009 | WO |
WO-2011030282 | Mar 2011 | WO |
WO-2011069145 | Jun 2011 | WO |
WO-2011114413 | Sep 2011 | WO |
WO-2011123685 | Oct 2011 | WO |
WO-2011162772 | Dec 2011 | WO |
WO-2012012127 | Jan 2012 | WO |
WO-2012114105 | Aug 2012 | WO |
WO-2013181352 | Dec 2013 | WO |
WO-2014022275 | Feb 2014 | WO |
WO-2014058945 | Apr 2014 | WO |
WO-2014085800 | Jun 2014 | WO |
WO-2014089186 | Jun 2014 | WO |
WO-2014099266 | Jun 2014 | WO |
WO-2016201406 | Dec 2016 | WO |
WO-2017041087 | Mar 2017 | WO |
WO-2018227191 | Dec 2018 | WO |
WO-2019055487 | Mar 2019 | WO |
WO-2019113505 | Jun 2019 | WO |
WO-2019232196 | Dec 2019 | WO |
WO-2020163744 | Aug 2020 | WO |
WO-2020185914 | Sep 2020 | WO |
WO-2022203747 | Sep 2022 | WO |
Entry |
---|
Arenas et al., “Asynchronous Testing of 2 Specimen-Diversion Devices to reduce Blood Culture Contamination: A Single-Site Product Supply Quality Improvement Project,” J. Emergency Nursing, vol. 47, No. 2, pp. 256-264.e6 (Mar. 2021), 15 pages. |
Arkin, C. F. et al., “Procedures for the Collection of Diagnostic Blood Specimens by Venipuncture; Approved Standard,” Fifth Edition, Clinical and Laboratory Standards Institute, vol. 23, No. 32 (2003), 52 pages. |
Barnard, D. R. & Arthur, M. M., “Fibronectin (cold insoluble globulin) in the neonate,” Clinical and Laboratory Observations, 102(3): 453-455 (1983). |
Bauman et al., “Don't Stick Me Again! Reducing Blood Culture Contamination,” INOVA Fairfax Medical Campus, Emergency Department (2019), 1 page. |
Baxter, “IV Tubing and Access Devices” authored by and published by Baxter, dated Nov. 6, 2006, 105 pages. |
BD Medical Surgical Systems Catalogue (Canadian Version), BD Medical, 2010, 51 pages. |
BD Saf-T-Intima Closed IV Catheter System, Becton, Dickinson and Company, 2015 Brochure. Retrieved from the Internet (Sep. 11, 2019) https://www.bd.com/en-us/offerings/capabilities/infusion- therapy/iv-catheters/bd-saf-tintima-closed-iv-catheter-system, 2 pages. |
BD Vacutainer Passive Shielding Blood Collection Needle Brochure; Becton Dickinson and Company (2005), 2 pages. |
Bell et al., Effectiveness of a Novel Specimen Collection System in Reducing Blood Culture Contamination Rates, J. Emergency Nursing, vol. 44, No. 6, 570 (Nov. 2018), 6 pages. |
Blakeney, “Reduction of Blood Culture Contaminations Using Initial Specimen Diversion Device,” Beebe Healthcare (Jun. 2018), 1 page. |
Brecher, M. E. et al., “Bacterial Contamination of Blood Components,” Clinical Microbiology Reviews, 18(1):195-204 (2005). |
Brownfield et al., “Emergency Department Observes 83% Reduction in Blood Culture Contamination with Initial Specimen Diversion Technology Adoption,” Am. J. Infection Control, vol. 49, S14, ADS 34 (Jun. 2021), 1 page. |
Calam, R. R., “Recommended ‘Order of Draw’ for Collecting Blood Specimens Into Additive-Containing Tubes,” Letter to the Editor, Clinical Chemistry, 28(6):1399 (1982), 1 page. |
Canadian Office Action for Canadian Application No. 3,120,161, dated Jun. 20, 2022, 4 pages. |
Canadian Office Action for Canadian Application No. 3,136,331, dated Feb. 21, 2023, 4 pages. |
Cartridge and Test Information, Abbott, Art: 714258-010 Rev. Date: Aug. 15, 2016, 6 pages. |
Case 1: 19-cv-00097-CFC-CJB, Magnolia Medical Technologies, Inc., Plaintiff v. Kurin, Inc., Defendant; Memorandum Opinion, (Document 514) filed Aug. 4, 2023, 38 pages. |
Case 1: 19-cv-00097-CFC-CJB, Magnolia Medical Technologies, Inc., Plaintiff v. Kurin, Inc., Defendant; Order, (Document 515) filed Aug. 4, 2023, 1 page. |
Case 1: 19-cv-00097-CFC-CJB, Magnolia Medical Technologies, Inc., Plaintiff v. Kurin, Inc., Defendant; Order, (Document 516) filed Aug. 4, 2023, 2 pages. |
Challiner, A. et al., Queen Alexandra Hospital, Portsmouth P06 3LY, “Venous/arterial blood management protection system,” Anaesthesia, Correspondence (Feb. 1992); 47(2), p. 169. |
Chang et al., “Impact of Blood Culture Diversion Device and Molecular Pathogen Identification on Vancomycin Use,” San Antonio Military Medical Center (2016), 1 page. |
Claim Construction Order in Retractable Technologies, Inc., and Thomas Shaw v. Becton Dickinson & Co., Civil Action No. 2:07-CV-250 (OF) (Jan. 20, 2009). 32 pages. |
Claim Construction Order, Magnolia Medical Techs. v. Kurin, Case No. 19-00097-CFC-CJB, at 3 (D. Del.) (May 20, 2020), 4 pages. |
De Korte, D. et al., “Diversion of first blood volume results in a reduction of bacterial contamination for whole-blood collections,” Vox Sanguinis, 83:13-16 (2002). |
De Korte, D. et al., “Effects of skin disinfection method, deviation bag, and bacterial screening on clinical safety of platelet transfusions in the Netherlands,” Transfusion, 46:476-485 (2006). |
Decision of Rejection for Japanese Application No. 2018-081980, dated Jan. 30, 2020, 11 pages. |
Declaration of Dr. Erik K. Antonsson, PH.D.. P.E., NAE (Mar. 21, 2023). 137 pages. |
Declaration of Dr. Morten Jensen under 37 C.F.R. § 1.132, Oct. 10, 2023, 56 pages. |
Doern et al., “A Comprehensive Update on the Problem of Blood Culture Contamination and a Discussion of Methods for Addressing the Problem,” Clinical Microbiology, vol. 33, No. 1, e00009-19 (Jan. 2020), 21 pages. |
Edwards Lifesciences, “Conservation. Safety. Simplicity. Edwards VAMP and VAMP Jr. Systems,” 2002 Brochure. Retrieved from the Internet (Sep. 11, 2019) https://www.medline.com/media/catalog/Docs/MKT/VAMPSYSTEMBROCHURE.PDF, 4 pages. |
Ernst, D. J. et al., “NCCLS simplifies the order of draw: a brief history,” MLO, pp. 26-27 (2004). |
European Examination Report for EP Application No. 17206745.6, dated Feb. 18, 2020, 4 pages. |
Examination Report for United Kingdom Application No. GB1805101.1, dated May 25, 2018, 8 pages. |
Exhibit 01—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 9,855,001 vs Barnard NPL, Aug. 30, 2019, 8 pages. |
Exhibit 02—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 9,855,001 vs BD Needle NPL, Aug. 30, 2019, 7 pages. |
Exhibit 03—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 9,855,001 vs U.S. Pat. No. 6,626,884, Aug. 30, 2019, 11 pages. |
Exhibit 04—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 9,855,001 vs U.S. Pat. Pub. No. 2005/161112, Aug. 30, 2019,22 pages. |
Exhibit 05—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 9,855,001 vs U.S. Pat. No. 4,673,386, Aug. 30, 2019, 21 pages. |
Exhibit 06—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 9,855,001 vs U.S. Pat. No. 4,904,240, Aug. 30, 2019, 15 pages. |
Exhibit 07—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 9,855,001 vs Leukotrap NPL, Aug. 30, 2019, 38 pages. |
Exhibit 09—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 9,855,001 vs U.S. Pat. No. 4,106,497, Aug. 30, 2019, 22 pages. |
Exhibit 10—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 9,855,001 vs Stopcock-Syringe NPL, Aug. 30, 2019, 85 pages. |
Exhibit 11—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 9,855,001 vs Ziegler NPL, Aug. 30, 2019, 8 pages. |
Exhibit 12—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,028,689 vs Barnard NPL, Aug. 30, 2019, 12 pages. |
Exhibit 13—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,028,689 vs U.S. Pat. No. 6,626,884, Aug. 30, 2019, 29 pages. |
Exhibit 14—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,028,689 vs U.S. Pat. Pub. No. 2005/161112, Aug. 30, 2019,48 pages. |
Exhibit 15—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,028,689 vs U.S. Pat. No. 4,673,386, Aug. 30, 2019, 44 pages. |
Exhibit 16—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,028,689 vs U.S. Pat. No. 4,904,240, Aug. 30, 2019, 31 pages. |
Exhibit 17—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,028,689 vs Leukotrap NPL, Aug. 30, 2019, 113 pages. |
Exhibit 19—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,028,689 vs U.S. Pat. No. 4,106,497, Aug. 30, 2019, 38 pages. |
Exhibit 20—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,028,689 vs Stopcock-Syringe NPL, Aug. 30, 2019, 268 pages. |
Exhibit 21—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,220,139 vs U.S. Pat. No. 6,626,884, Aug. 30, 2019, 35 pages. |
Exhibit 22—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,220,139 vs U.S. Pat. Pub. No. 2005/161112, Aug. 30, 2019,46 pages. |
Exhibit 23—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,220,139 vs U.S. Pat. No. 4,207,870, Aug. 30, 2019, 20 pages. |
Exhibit 24—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,220,139 vs U.S. Pat. No. 6,506,182, Aug. 30, 2019, 15 pages. |
Exhibit 25—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,220,139 vs U.S. Pat. No. 4,673,386, Aug. 30, 2019, 53 pages. |
Exhibit 26—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,220,139 vs U.S. Pat. No. 4,904,240, Aug. 30, 2019, 39 pages. |
Exhibit 27—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,220,139 vs Leukotrap NPL, Aug. 30, 2019, 115 pages. |
Exhibit 29—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,220,139 vs U.S. Pat. No. 4, 106,497, Aug. 30, 2019, 45 pages. |
Exhibit 30—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,220,139 vs Stopcock-Syringe NPL, Aug. 30, 2019, 246 pages. |
Exhibit 31—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,220,139 vs U.S. Pat. No. 4,349,035, Aug. 30, 2019, 26 pages. |
Exhibit 32—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,220,139 vs U.S. Pat. Pub. No. 2008/0145933A1, Aug. 30, 2019, 39 pages. |
Exhibit 33—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,039,483 vs Barnard NPL, Aug. 30, 2019, 14 pages. |
Exhibit 34—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,039,483 vs U.S. Pat. No. 6,626,884, Aug. 30, 2019, 22 pages. |
Exhibit 35—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,039,483 vs U.S. Pat. Pub. No. 2005/161112, Aug. 30, 2019,45 pages. |
Exhibit 36—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,039,483 vs U.S. Pat. No. 4,673,386, Aug. 30, 2019, 47 pages. |
Exhibit 37—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,039,483 vs U.S. Pat. No. 4,904,240, Aug. 30, 2019, 30 pages. |
Exhibit 38—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,039,483 vs Leukotrap NPL, Aug. 30, 2019, 115 pages. |
Exhibit 40—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,039,483 vs U.S. Pat. No. 4, 106,497, Aug. 30, 2019, 45 pages. |
Exhibit 41—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,039,483 vs Stopcock-Syringe NPL, Aug. 30, 2019, 214 pages. |
Exhibit 42—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,039,483 vs U.S. Pat. Pub. No. 2008/0145933A1, Aug. 30, 2019, 38 pages. |
Extended European Search Report dated Aug. 30, 2021 for European Application No. 20207898.6, 8 pages. |
Extended European Search Report for Application No. EP18855938.9, mailed on Aug. 2, 2021, 7 pages. |
Extended European Search Report for Application No. EP21167069.0, mailed on Nov. 10, 2021, 9 pages. |
Extended European Search Report for EP Application No. 17204012.3, dated Feb. 14, 2018, 7 pages. |
Extended European Search Report for EP Application No. 17206745.6, dated Feb. 19, 2018, 8 pages. |
Extended European Search Report for EP Application No. 18188136.8, dated May 16, 2019, 9 pages. |
Extended European Search Report for European Application No. 21167625.9, dated Oct. 8, 2021, 7 pages. |
Extended European Search Report for European Application No. 22172183.0, dated Sep. 11, 2022, 7 pages. |
Extended European Search Report for European Application No. 22194769.0, dated Feb. 28, 2023, 9 pages. |
Extended European Search Report for European Application No. 23153164.1, dated Aug. 7, 2023, 8 pages. |
Extended European Search Report for European Application No. EP22210589.2 dated Apr. 17, 2023, 6 pages. |
File History of U.S. Appl. No. 15/832,091, filed Dec. 5, 2017, 360 pages. |
Final Office Action for U.S. Appl. No. 17/591,237 dated Aug. 25, 2023, 25 pages. |
Final Office Action for U.S. Appl. No. 17/591,239 dated Aug. 23, 2023, 23 pages. |
Final Office Action for U.S. Appl. No. 17/591,237, filed Aug. 4, 2022, 26 pages. |
Final Office Action for U.S. Appl. No. 17/591,239, filed Aug. 4, 2022, 26 pages. |
Final Rejection Office Action for U.S. Appl. No. 17/684,920 mailed on Jan. 31, 2023, 9 pages. |
First Amended Complaint in Magnolia Medical Technologies, Inc. v. Kurin, Inc., C.A. No. 19-cv-00097-CFC, Document 5 (Filed Mar. 7, 2019). 40 pages. |
Geisler et al., “Model to Evaluate the Impact of Hospital-Based Interventions Targeting False-Positive Blood Cultures on Economic and Clinical Outcomes,” J. Hospital Infection, vol. 102, No. 4, pp. 438-444 (Mar. 2019). |
Gottlieb, T., “Hazards of Bacterial Contamination of Blood Products,” Anaesth Intens Care, 21:20-23 (1993). |
Hall, K. K. et al., “Updated Review of Blood Culture Contamination,” Clinical Microbiology Reviews, 19(4):788-802 (2006). |
Hillyer, C. D. et al., “Bacterial Contamination of Blood Components Risks, Strategies, and Regulation,” Hematology, 575-589 (2003). |
Indian Office Action for Application No. 202017008581dated Mar. 8, 2022, 7 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2007/087951, dated May 16, 2008, 8 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2013/043289, dated Oct. 24, 2013, 15 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2013/052493, dated Nov. 27, 2013, 7 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2013/063975, dated Mar. 20, 2014, 16 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2013/071491, dated Aug. 5, 2014, 9 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2013/072563, dated Feb. 7, 2014, 11 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2013/073080, dated Feb. 18, 2014, 14 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2018/050621, dated Feb. 26, 2018, 11 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2019/034626, dated Aug. 22, 2019, 16 pages. |
Kim, J. Y. et al., “The Sum of the Parts is Greater Than the Whole: Reducing Blood Culture Contamination,” Annals of Internal Medicine, 154:202-203 (2011). |
Kurin, Inc.'s Opening Post-Trial Brief Regarding indefiniteness in Magnolia Medical Technologies, Inc. v. Kurin, Inc., C.A. No. 19-097 (CFC)(CJB), Document 463 (Filed Sep. 30, 2022), 24 pages. |
Lanteri et al., “Reduction of Blood Culture Contaminations in the Emergency Department,” Department of Emergency Medicine, San Antonio Military Medical Center (2016), 1 page. |
Levin, P. D. et al., “Use of the Nonwire Central Line Hub to Reduce Blood Culture Contamination,” Chest, 143(3):640-645 (2013). |
Litigation Search Report CRU 3999 for Reexamination U.S. Appl. No. 90/019,177 dated Mar. 23, 2023, 95 pages. |
Liumbruno, G. M. et al., “Reduction of the risk of bacterial contamination of blood components through diversion of the first part of the donation of blood and blood components,” Blood Transfus, 7:86-93 (2009). |
Li, Y. et al., “Direct labeling and visualization of blood vessels with lipophilic carbocyanine dye Oil,” Nature Protocols, 3(11):1703-1708 (2008). |
Magnolia's Answer Brief in Opposition to Kurin, Inc.'s Opening Post-Trial Brief Regarding Indefiniteness in Magnolia Medical Technologies, Inc. v. Kurin, Inc., C.A. No. 19-097 (CFC)(CJB), Document 463 (Filed Sep. 30, 2022). 25 pages. |
Mayer, G. A, “A Method for the Reliable Determination of Clotting Time in Whole Blood,” Can Med Assoc J., 72(12):927-929 (1955). |
McDonald, C. P., “Interventions Implemented to Reduce the Risk of Transmission of Bacteria by Transfusion in the English National Blood Service,” Transfus Med Hemother, 38:255-258 (2011). |
Meissner, G. F. et al., “A Method Based on the Use of Whole Venous Blood in Capillary Tubes,” American Journal of Clinical Pathology, 33(2):29-31 (1963). |
Murphy, M., “Better Blood Transfusion,” Journal of the Intensive Core Society, 4(3):78-80 (2003). |
Napolitano, M. et al., “Quality control of bacterial contamination of blood components: the feasibility of diversion system testing,” Blood Transfus, 2:231-232 (2004). |
Nielsen et al., “Initial Specimen Diversion Device Reduces Blood Culture Contamination and Vancomycin Use in Academic Medical Centre,” J. Hospital Infection, vol. 120:127-133 (Feb. 2022). |
Non Final Office Action for U.S. Appl. No. 16/789,034 dated Feb. 9, 2023, 11 pages. |
Non Final Office Action for U.S. Appl. No. 17/591,239 dated Feb. 17, 2023, 34 pages. |
Non-Final Office Action for U.S. Appl. No. 17/863,605, dated Nov. 28, 2023, 15 pages. |
Non-Final Office Action for U.S. Appl. No. 18/381,369, dated Nov. 28, 2023, 16 pages. |
Non-Final Office Action for U.S. Appl. No. 16/815,526 mailed on Aug. 18, 2022, 13 pages. |
Non-Final Office Action for U.S. Appl. No. 17/138,056 mailed on Dec. 21, 2022, 11 pages. |
Non-Final Office Action for U.S. Appl. No. 17/390,249 dated Nov. 8, 2023, 9 pages. |
Non-Final Office Action for U.S. Appl. No. 17/591,237, dated Feb. 16, 2023, 34 pages. |
Non-Final Office Action for U.S. Appl. No. 17/710,401 mailed on Jul. 6, 2022, 22 pages. |
Non-Final Office Action for U.S. Patent Application No. 16/379, 128, Apr. 26, 2022, 14 pages. |
Non-Final Office Action for U.S. Appl. No. 17/591,239, filed May 3, 2022, 20 pages. |
Non-Final Office Action for U.S. Appl. No. 17/710,389, filed Jun. 16, 2022, 25 pages. |
Non-final Rejection for U.S. Appl. No. 17/388,971 dated Nov. 23, 2021, 19 pages. |
Norberg, A et al., “Contamination Rates of Blood Cultures Obtained by Dedicated Phlebotomy vs Intravenous Catheter,” JAMA, 289(6):726-729 (2003). |
Notice of Reasons for Rejection for Japanese Application No. 2015-545813, dated Jul. 4, 2017, 14 pages. |
Notice of Reasons for Rejection for Japanese Application No. 2018-081980, dated Feb. 21, 2019, 7 pages, with English translation. |
Notice of Reasons for Rejection for Japanese Application No. 2019-230734, dated Jan. 22, 2021, 9 pages. |
Notice of Reasons for Rejection for Japanese Application No. 2020-075727, dated Jul. 21, 2021, with English translation, 37 pages. |
Notice of Reasons for Rejection for Japanese Application No. 2020-094488, dated Aug. 2, 2021, 4 pages, with English translation. |
Notice of Reasons for Rejection for Japanese Application No. 2020-094488, dated Mar. 31, 2022, 6 pages, with English translation. |
Notification of the First Office Action for Chinese Application No. 201380040468.7, dated Jun. 30, 2016, 9 pages, with English translation. |
Notification of the First Office Action for Chinese Application No. 201380072185.0, dated Sep. 28, 2016, 17 pages. |
Notification of the First Office Action for Chinese Application No. 201880066848.0, dated Apr. 20, 2022, 20 pages. |
Office Action for Australian Application No. AU20180334138 dated Jun. 24, 2023, 3 pages. |
Office Action for Australian Application No. AU20220200818 dated May 11, 2023, 04 pages. |
Office Action for Chinese Application No. 201811146373.4, dated Nov. 4, 2020, with English language translation, 17 pages. |
Office Action for Chinese Application No. 201811146373.4, mailed Aug. 25, 2021, 10 pages, with English translation. |
Office Action for Chinese Application No. 201811146373.4, mailed Jan. 29, 2022, 21 pages, with English translation. |
Office Action for Japanese application No. JP20200511930, mailed on Aug. 23, 2022, 9 pages. |
Office Action for Japanese Application No. JP20200566232 dated Apr. 12, 2023, 27 pages. |
Office Action for Japanese Application No. JP2022184274 dated Oct. 27, 2023, 6 pages. |
Office Action for U.S. Appl. No. 11/955,635, dated Dec. 3, 2010, 11 pages. |
Office Action for U.S. Appl. No. 11/955,635, dated Jul. 22, 2010, 11 pages. |
Office Action for U.S. Appl. No. 13/335,241, dated Apr. 20, 2012, 12 pages. |
Office Action for U.S. Appl. No. 13/458,508, dated Jul. 24, 2012, 13 pages. |
Office Action for U.S. Appl. No. 13/675,295, dated May 23, 2013, 15 pages. |
Office Action for U.S. Appl. No. 13/954,528, dated Mar. 17, 2014, 10 pages. |
Office Action for U.S. Appl. No. 14/049,326, dated Apr. 24, 2015, 10 pages. |
Office Action for U.S. Appl. No. 14/089,267, dated Jun. 19, 2014, 13 pages. |
Office Action for U.S. Appl. No. 14/493,796, dated Jan. 27, 2015, 7 pages. |
Office Action for U.S. Appl. No. 14/494,208, dated Jan. 27, 2015, 7 pages. |
Office Action for U.S. Appl. No. 14/498,102, dated Oct. 17, 2017, 20 pages. |
Office Action for U.S. Appl. No. 14/498,102, dated Sep. 24, 2018, 18 pages. |
Office Action for U.S. Appl. No. 14/662,676, dated Sep. 5, 2018, 25 pages. |
Office Action for U.S. Appl. No. 14/712,437 dated Oct. 25, 2018, 20 pages. |
Office Action for U.S. Appl. No. 14/838,794, dated Aug. 3, 2017, 8 pages. |
Office Action for U.S. Appl. No. 15/088,842, dated Nov. 23, 2016, 20 pages. |
Office Action for U.S. Appl. No. 15/432,310, dated Apr. 12, 2017, 14 pages. |
Office Action for U.S. Appl. No. 15/435,684, dated Jun. 12, 2017, 19 pages. |
Office Action for U.S. Appl. No. 15/448,891, dated Jun. 16, 2017, 25 pages. |
Office Action for U.S. Appl. No. 15/457,082, dated Jun. 15, 2017, 22 pages. |
Office Action for U.S. Appl. No. 15/829,015, dated Feb. 6, 2018, 24 pages. |
Office Action for U.S. Appl. No. 15/829,018, dated Feb. 16, 2018, 13 pages. |
Office Action for U.S. Appl. No. 15/829,023, dated Feb. 7, 2018, 25 pages. |
Office Action for U.S. Appl. No. 15/832,055, dated Feb. 8, 2018, 21 pages. |
Office Action for U.S. Appl. No. 15/832,087, dated Feb. 7, 2018, 24 pages. |
Office Action for U.S. Appl. No. 15/832,091, dated Feb. 22, 2018, 16 pages. |
Office Action for U.S. Appl. No. 15/854,273, dated Jan. 13, 2020, 13 pages. |
Office Action for U.S. Appl. No. 15/854,273, dated Mar. 15, 2019, 19 pages. |
Office Action for U.S. Appl. No. 15/854,273, dated Sep. 7, 2018, 15 pages. |
Office Action for U.S. Appl. No. 16/129,066, dated Sep. 3, 2020, 13 pages. |
Office Action for U.S. Appl. No. 16/255,055, dated Mar. 18, 2019, 16 pages. |
Office Action for U.S. Appl. No. 16/255,058, dated Mar. 30, 2021, 16 pages. |
Office Action for U.S. Appl. No. 16/299,962, dated Dec. 26, 2019, 14 pages. |
Office Action for U.S. Appl. No. 16/299,962, dated Dec. 9, 2020, 15 pages. |
Office Action for U.S. Appl. No. 16/299,962, dated Jun. 15, 2021, 17 pages. |
Office Action for U.S. Appl. No. 16/299,962, dated May 2, 2019, 14 pages. |
Office Action for U.S. Appl. No. 16/376,745, dated May 14, 2021, 13 pages. |
Office Action for U.S. Appl. No. 16/426,380, dated May 7, 2021, 28 pages. |
Office Action for U.S. Appl. No. 16/426,380, dated Oct. 30, 2020, 29 pages. |
Office Action for U.S. Appl. No. 17/388,979, dated Dec. 8, 2021, 21 pages. |
Office Action for U.S. Appl. No. 17/525,682, dated Feb. 7, 2022, 12 pages. |
Office Action for U.S. Appl. No. 17/532,382, dated Feb. 7, 2022, 10 pages. |
Office Action for U.S. Appl. No. 17/591,237, dated May 3, 2022, 20 pages. Examiner. |
Office Action for U.S. Appl. No. 17/684,920, dated Jul. 11, 2022, 12 pages. |
Office Action for U.S. Appl. No. 17/710,411, dated Jul. 6, 2022, 22 pages. |
Office Action in Ex Parte Reexamination for U.S. Appl. No. 90/019,177, dated Aug. 9, 2023, 11 pages. |
Opening Expert Report of Dr. Juan G. Santiago Regarding Infringement of U.S. Pat. No. 9,855,001 and U.S. Pat. No. 10,039,483 (Redacted) in Magnolia Medical Technologies, Inc. v. Kurin, Inc., CA No. 19-00097-CFC (dated Jan. 15, 2021), 555 pages. |
Order of Draw for Multiple Tube Collections, LabNotes, a newsletter from BD Diagnostics,—Preanalytical Systems, 17(1):3 (2007), 1 page. |
Original Claims of U.S. Appl. No. 14/712,431, filed May 14, 2015. 6 pages. |
Page, C. et al., “Blood conservation devices in critical care: a narrative review,” Annals of Intensive Care, 3:14 (2013), 6 pages. |
Palavecino, E. L. et al., “Detecting Bacterial Contamination in Platelet Products,” Clin. Lab., 52:443-456 (2006). |
Pall Corp., “Leukotrap Filtration Systems for Whole Blood Derived Platelets: Leukotrap RC PL and Leukotrap PL Systems,” 2005 Brochure, 2 pages. |
Patton, R. G. et al., “Innovation for Reducing Blood Culture Contamination: Initial Specimen Diversion Technique,” Journal of Clinical Microbiology, 48(12):4501-4503 (2010). |
Perez, P. et al., “Multivariate analysis of determinants of bacterial contamination of whole-blood donations,” Vox Sanguinis, 82:55-60 (2002). |
Povroznik, “Initial Specimen Diversion Device Utilization Mitigates Blood Culture Contamination Across Regional Community Hospital and Acute Care Facility,” Am. J. Medical Quality, vol. 37, No. 5, 405 (Mar. 2022), 8 pages. |
Proehl, J. A et al., “Clinical Practice Guideline: Prevention of Blood Culture Contamination, Full Version,” 2012 ENA Emergency Nurses Resources Development Committee, Emergency Nurses Association (Dec. 2012), 14 pages. |
Quilici, N. et al., “Differential Quantitative Blood Cultures in the Diagnosis of Catheter-Related Sepsis in Intensive Care Units,” Clinical Infectious Diseases 25:1066-1070 (1997). |
Redacted Plaintiff's Answering Brief in Opposition to Defendant's Motion for Summary Judgement (No. 3) Of Noninfringement of All Asserted Claims Due to Lack of Sequestration in Magnolia Medical Technologies, Inc. v. Kurin, Inc., C.A. No. 19-97 (CFC)(CJB), Document 389 (Filed Jul. 14, 2021), 15 pages. |
Reexamination Request Order-Granted, for U.S. Appl. No. 90/019,177, mailed Apr. 26, 2023, 16 pages. |
Request for Ex Parte Reexamination Under 35 U.S.C. 302 and 37 C.F.R. 1.510 filed Mar. 22, 2023, 84 pages. |
Rupp et al., “Reduction in Blood Culture Contamination Through Use of Initial Specimen Diversion Device,” Clinical Infectious Diseases, vol. 65, No. 2, 201 (Jul. 15, 2017), 19 pages. |
Schuur, J., “Blood Cultures: When Do they Help and When Do They Harm?” Brigham & Women's Hospital, Department of Emergency Medicine, (June 21-23, 2012), 42 pages. |
Sheppard, C. A et al., “Bacterial Contamination of Platelets for Transfusion: Recent Advances and Issues,” LabMedicine, 36(12):767-770 (2005). |
Shulman, G., “Quality of Processed Blood for Autotransfusion,” The Journal of Extra-Corporeal Technology, 32(1):11-19 (2000). |
Sibley, C. D. et al., “Molecular Methods for Pathogen and Microbial Community Detection and Characterization: Current and Potential Application in Diagnostic Microbiology,” Infection, Genetics and Evolution 12:505-521 (2012). |
Skoglund et al., “Estimated Clinical and Economic Impact through Use of a Novel Blood Collection Device To Reduce Blood Culture Contamination in the Emergency Department: a Cost-Benefit Analysis,” J Clin Microbiol. (Jan. 2019); 57(1):e01015-18, 10 pages. |
Steed et al., “Study Demonstrates Reduction in Blood Culture Contamination Rates with Novel Blood Culture Collection Device,” Clinical Lab Products Magazine (Feb. 2018), 2 pages. |
Stohl, S. et al., “Blood Cultures at Central Line Insertion in the Intensive Care Unit: Comparison with Peripheral Venipuncture,” Journal of Clinical Microbiology, 49(7):2398-2403 (2011). |
Supplementary European Search Report for EP Application No. 13797732.8, dated Dec. 7, 2015, 5 pages. |
Supplementary European Search Report for EP Application No. 13845555.5, dated Jul. 12, 2016, 9 pages. |
Supplementary European Search Report for EP Application No. 13860741.1, dated Jun. 7, 2016, 5 pages. |
Tang, M. et al., “Closed Blood Conservation Device for Reducing Catheter-Related Infections in Children After Cardiac Surgery,” Critical Care Nurse, 34(5):53-61 (2014). |
Tompkins et al., “Getting to Zero: Impact of A Device To Reduce Blood Culture Contamination and False-Positive Central-Line-Associated Bloodstream Infection,” Infection Control & Hospital Epidemiology, pp. 1-5 (Nov. 2022). |
Tongma et al., “Significant Reduction of Blood Culture Contamination in the Emergency Department (ED) Using the Steripath® Blood Diversion Device,” Open Forum Infectious Diseases, vol. 4, Supp. 1, 2035 (Oct. 2017), 1 page. |
Vent Definition & Meaning—Merriam-Webster (https://www.merriam-webster.com/dictionary/vent, accessed Mar. 21, 2023). 16 pages. |
Vent, n.2: Oxford English Dictionary (https://www.oed.com/view/Entry/222207?&print, accessed Feb. 16, 2023), 12 pages. |
Verdict Form (Phase 2) (Redacted) in Magnolia Medical Technologies, Inc. v. Kurin, Inc., CA No. 19-97-CFC (CJB), Document 443 (Filed Jul. 29, 2022), 5 pages. |
Verdict Form (Redacted) in Magnolia Medical Technologies, Inc. v. Kurin, Inc., C.A. No. 19-97-CFC (CJB), Document 437 (Filed Jul. 26, 2022), 3 pages. |
Wagner et al., “Diversion of Initial Blood Flow to Prevent Whole-Blood Contamination by Skin Surface Bacteria: an in vitro model,” Transfusion, 40:335-338 (2000). |
Wang, P. et al., “Strategies on Reducing Blood Culture Contamination,” Reviews in Medical Microbiology, 23: pp. 63-66 (2012). |
Weinbaum, F. I. et al., “Doing It Right the First Time: Quality Improvement and the Contaminant Blood Culture,” Journal of Clinical Microbiology, 35(3):563-565 (1997). |
Weinstein, M.P., “Current Blood Culture Methods and Systems: Clinical Concepts, Technology, and Interpretation of Results,” Clinical Infectious Diseases, 23:40-46 (1996). |
Weinstein, M.P. et al., “The Clinical Significance of Positive Blood Cultures in the 1990s: A Prospective Comprehensive Evaluation of the Microbiology, Epidemiology, and Outcome of Bacteremia and Fungemia in Adults,” Clinical Infectious Diseases, 24:584-602 (1997). |
Weinstein, M.P., “Minireview: Blood Culture Contamination: Persisting Problems and Partial Progress,” Journal of Clinical Microbiology, 41(6):2275-2278 (2003). |
Ziegler, et al., “Controlled Clinical Laboratory Comparison of Two Supplemented Aerobic and Anaerobic Media Used in Automated Blood Culture Systems To Detect Bloodstream Infections,” J. Clinical Microbiology, 36(3):657-661 (1998). |
Zimmerman et al., “Reducing Blood Culture Contamination Using an Initial Specimen Diversion Device,” Am. J. Infection Control, vol. 47, No. 7, pp. 822-826 (Jan. 2019). |
Zimmon, D. S.. et al., “Effect of Portal Venous Blood Flow Diversion on Portal Pressure,” J Clin Invest, 65(6):1388-1397 (1980). |
Zundert, A V., “New Closed IV Catheter System,” Acta Anaesth. Belg., 56:283-285 (2005). |
Extended European Search Report for European Application No. 23218666.8 dated Apr. 18, 2024, 9 pages. |
Extended European Search Report for European Application No. EP 2023029844.2 dated Mar. 20, 2024, 9 pages. |
JP Application No. 2023-075104 Notice of Reasons for Rejection dated Feb. 29, 2024, mailed Mar. 5, 2024, with English Translation, 9 pages. |
Non-Final Office Action for U.S. Appl. No. 17/136,882, dated Apr. 19, 2024, 8 pages. |
Non-Final Office Action for U.S. Appl. No. 18/227,185 dated Apr. 18, 2024, 18 pages. |
Non-Final Office Action for U.S. Appl. No. 18/380,259 dated Jan. 29, 2024, 33 pages. |
Office Action for Israeli Application No. 285289, dated May 6, 2024, 4 pages. |
Office Action for Israeli Application No. 286263, dated May 12, 2024, 4 pages. |
Office Action for U.S. Appl. No. 17/403,500, dated May 20, 2024, 28 pages. |
U.S. Appl. No. 18/407,010 Non-Final Office Action dated Mar. 13, 2024, 8 pages. |
Office Action for Japanese Application No. 2022-184274, mailed Jun. 14, 2024, with English Translation, 4 pages. |
Office Action for Japanese Application No. 2022-212405, mailed Jun. 20, 2024, with English translation, 6 pages. |
Office Action for U.S. Appl. No. 18/240,178, mailed Jun. 12, 2024, 16 pages. |
Office Action for Israeli Application No. 309638, mailed Jul. 16, 2024, 3 pages. |
Office Action for U.S. Appl. No. 18/675,824, mailed Jul. 26, 2024, 13 pages. |
AVATAR: “Is it safe to reinfuse blood drawn from a CVAD via a syringe when checking line patency or drawing blood?” [retrieved online Jul. 31, 2024] URL:https://www.avatargroup.org.au/faq---blood-collection.html, 4 pages. |
Bruneau, Cecile, et al.; “Efficacy of a new collection procedure for preventing bacterial contamination of whole-blood donations,” Transfusion (2001); 41(1):74-81. |
Exhibit A1—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 9,855,002 vs U.S. Patent Publication No. 2005/0161112 A1, Jul. 29, 2024, 234 pages. |
Exhibit A10—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 9,855,002 vs PortSyringe NPL, Jul. 29, 2024, 230 pages. |
Exhibit A11—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 9,855,002 vs U.S. Pat. No. 4,056,101 NPL, Jul. 29, 2024, 111 pages. |
Exhibit A12—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 9,855,002 vs U.S. Pat. No. 5,947,932, Jul. 29, 2024, 156 pages. |
Exhibit A2—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 9,855,002 vs Japanese Patent Publication No. H10-2112742, Jul. 29, 2024, 281 pages. |
Exhibit A3—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 9,855,002 vs U.S. Patent Publication No. 2007/0119508, Jul. 29, 2024, 368 pages. |
Exhibit A4—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 9,855,002 vs U.S. Pat. No. 5,573,951, Jul. 29, 2024, 258 pages. |
Exhibit A5—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 9,855,002 vs U.S. Pat. No. 6,626,884, Jul. 29, 2024, 116 pages. |
Exhibit A6—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 9,855,002 vs U.S. Pat. No. 4,673,386, Jul. 29, 2024, 145 pages. |
Exhibit A7—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 9,855,002 vs U.S. Pat. No. 4,904,240, Jul. 29, 2024, 147 pages. |
Exhibit A8—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 9,855,002 vs Leukotrap NPL, Jul. 29, 2024, 144 pages. |
Exhibit A9—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 9,855,002 vs U.S. Pat. No. 4,106,497, Jul. 29, 2024, 194 pages. |
Exhibit B1—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,052,053 vs U.S. Patent Publication No. 2005/0161112 A1, Jul. 29, 2024, 237 pages. |
Exhibit B10—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,052,053 vs PortSyringe NPL, Jul. 29, 2024, 229 pages. |
Exhibit B11—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,052,053 vs U.S. Pat. No. 4,056,101 NPL, Jul. 29, 2024, 107 pages. |
Exhibit B12—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,052,053 vs U.S. Pat. No. 5,947,932, Jul. 29, 2024, 154 pages. |
Exhibit B2—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,052,053 vs Japanese Patent Publication No. H10-2112742, Jul. 29, 2024, 265 pages. |
Exhibit B3—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,052,053 vs U.S. Patent Publication No. 2007/0119508, Jul. 29, 2024, 373 pages. |
Exhibit B4—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,052,053 vs U.S. Pat. No. 5,573,951, Jul. 29, 2024, 264 pages. |
Exhibit B5—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,052,053 vs U.S. Pat. No. 6,626,884, Jul. 29, 2024, 125 pages. |
Exhibit B6—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,052,053 vs U.S. Pat. No. 4,673,386Jul. 29, 2024, 146 pages. |
Exhibit B7—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,052,053 vs U.S. Pat. No. 4,904,240, Jul. 29, 2024, 143 pages. |
Exhibit B8—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,052,053 vs Leukotrap NPL, Jul. 29, 2024, 136 pages. |
Exhibit B9—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 10,052,053 vs U.S. Pat. No. 4,106,497, Jul. 29, 2024, 191 pages. |
Exhibit C1—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 11,529,081 vs U.S. Patent Publication No. 2005/0161112 A1, Jul. 29, 2024, 363 pages. |
Exhibit C2—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 11,529,081 vs U.S. Pat. Nos. 9,855,002 and 10,052,053, Jul. 29, 2024, 488 pages. |
Exhibit C3—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 11,529,081 vs U.S. Pat. No. 4,312,362, Jul. 29, 2024, 354 pages. |
Exhibit C4—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 11,529,081 vs Kurin Lock NPL, Jul. 29, 2024, 361 pages. |
Exhibit C5—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 11,529,081 vs U.S. Pat. No. 4,207,870, Jul. 29, 2024, 230 pages. |
Exhibit C6—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 11,529,081 vs U.S. Patent Publication No. 2018/0177445, Jul. 29, 2024, 479 pages. |
Exhibit C7—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 11,529,081 vs U.S. Pat. No. 9,820,682, Jul. 29, 2024, 338 pages. |
Exhibit D1—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 11,653,863 vs U.S. Patent Publication No. 2005/0161112 A1, Jul. 29, 2024, 369 pages. |
Exhibit D2—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 11,653,863 vs U.S. Pat. Nos. 9,855,002 and 10,052,053, Jul. 29, 2024, 481 pages. |
Exhibit D3—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 11,653,863 vs U.S. Pat. No. 4,312,362, Jul. 29, 2024, 334 pages. |
Exhibit D4—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 11,653,863 vs Kurin Lock NPL, Jul. 29, 2024, 363 pages. |
Exhibit D5—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 11,653,863 vs U.S. Pat. No. 4,207,870, Jul. 29, 2024, 219 pages. |
Exhibit D6—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 11,653,863 vs U.S. Patent Publication No. 2018/0177445, Jul. 29, 2024, 447 pages. |
Exhibit D7—Defendant's Invalidity Contentions, Invalidity Claim Chart —U.S. Pat. No. 11,653,863 vs U.S. Pat. No. 9,820,682, Jul. 29, 2024, 309 pages. |
Exhibit E1—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 11,903,709 vs U.S. Pat. Publication No. 2005/0161112 A1, Jul. 29, 2024, 442 pages. |
Exhibit E2—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 11,903,709 vs U.S. Pat. Nos. 9,855,002 and 10,052,053, Jul. 29, 2024, 517 pages. |
Exhibit E3—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 11,903,709 vs U.S. Pat. No. 4,312,362, Jul. 29, 2024 , 438 pages. |
Exhibit E4—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 11,903,709 vs Kurin Lock NPL, Jul. 29, 2024, 365 pages. |
Exhibit E5—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 11,903,709 vs U.S. Pat. No. 4,207,870, Jul. 29, 2024, 351 pages. |
Exhibit E6—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 11,903,709 vs U.S. Patent Publication No. 2018/0177445, Jul. 29, 2024, 559 pages. |
Exhibit E7—Defendant's Invalidity Contentions, Invalidity Claim Chart—U.S. Pat. No. 11,903,709 vs U.S. Pat. No. 9,820,682, Jul. 29, 2024, 419 pages. |
McDonald, C.P.; “Bacterial risk reduction by improved donor arm disinfection, diversion and bacterial screening,” Transfus Med., (2006); 16(6):381-396. |
Office Action for Australian Application No. 2020218544, mailed Jul. 31, 2024, 3 pages. |
Office Action for U.S. Appl. No. 18/676,186, mailed Aug. 5, 2024, 13 pages. |
Patel, R. et al., “Optimized Pathogen Detection with 30- Compared to 20-Milliliter Blood Culture Draws.” Journal of Clinical Microbiology, 49(12):4047-4051 (2011). |
Office Action for Canadian Application No. 3183294, mailed Aug. 19, 2024, 5 pages. |
Number | Date | Country | |
---|---|---|---|
20240131258 A1 | Apr 2024 | US |
Number | Date | Country | |
---|---|---|---|
61712468 | Oct 2012 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14049326 | Oct 2013 | US |
Child | 14838794 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16789034 | Feb 2020 | US |
Child | 18399007 | US | |
Parent | 16255055 | Jan 2019 | US |
Child | 16789034 | US | |
Parent | 15899856 | Feb 2018 | US |
Child | 16255055 | US | |
Parent | 14838794 | Aug 2015 | US |
Child | 15899856 | US |